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SUMMARY 
Systemic iron homeostasis is essential for human health. Its maintenance critically 
depends on the interaction between the hepatic hormone hepcidin and the sole known 
iron exporter ferroportin (FPN) predominantly expressed in hepatocytes, duodenal 
enterocytes and macrophages. Hepcidin binding leads to FPN internalization and 
degradation resulting in cellular iron retention. 
Iron is an essential nutrient also for pathogens and plays a central role in host-pathogen 
interactions. The innate immune system fights infections by sequestration of iron in 
macrophages of the reticuloendothelial system. The resulting hypoferremia represents a 
major host defence strategy. A current model posits that hepcidin is the crucial effector 
of this response, as its release from macrophages and hepatocytes provokes FPN 
protein decrease and, consequently, tissue iron retention. 
The aim of my PhD project was to identify novel cellular regulators of hepcidin-mediated 
ferroportin (FPN) degradation, a fundamental process that controls systemic iron 
homeostasis. To reach this aim I generated a HeLa cell line expressing a hFPN-renilla 
fusion protein, which was used for a focused high-throughput RNAi screen targeting 
kinases and related proteins. Out of 779 genes tested, the screen identified 71 putative 
regulators of FPN protein stability. Validation experiments confirmed the phenotype of 
24 genes. Interestingly, most validated regulators of FPN expression conferred 
hepcidin-independent FPN regulation. From these I selected 14 genes associated with 
immune processes for further characterization in murine bone marrow-derived 
macrophages (BMDMs). Finally, my studies focused on Toll-like receptor 6 (TLR6) as 
an effective regulator of FPN expression in BMDMs and I investigated how the TLR6 
activation pathway modulates iron regulation in the inflammatory context. TLR2/6 
ligation by the synthetic lipoprotein derived from Mycoplasma: FSL1 triggered a 
profound decrease in FPN mRNA and protein expression in BMDMs as well as in the 
liver and the spleen of mice. Unexpectedly hepcidin expression remained unchanged. 
Hepcidin-independent FPN down regulation was a conserved response to different 
microbial lipopeptides and elicited a fast, hepcidin-independent hypoferremia pathway. 
These findings were further confirmed in C326S FPN knock-in mice with a disrupted 
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hepcidin/FPN regulatory circuitry. This work challenges the prevailing role of hepcidin in 
inflammatory hypoferremia and suggests that rapid hepcidin-independent FPN down 
regulation may represent the first line response to restrict iron access to pathogens.
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ZUSAMMENFASSUNG 
Systemische Eisenhomeoestase ist essentiell für die Gesundheit des Menchsen. Ihre 
Aufrechterhaltung hängt entscheidend von dem Zusammenspiel zwischen dem 
hepatischen Hormon Hepcidin und dem einzigen bekannten Eisen-Exporter, Ferroportin 
(FPN), der überwiegend in Hepatozyten, duodenalen Enterozyten und Makrophagen 
exprimiert wird, ab. Die Bindung von Hepcidin an FPN führt zu Internalisierung und 
Abbau von FPN, was somit die Freisetzung von Eisen verhindert.  
Auch für Pathogene ist Eisen ein essentieller Nährstoff und spielt eine zentrale Rolle in 
der Interaktion von Wirt und Pathogen. Das angeborene Immunsystem nutzt die 
Zurückhaltung von Eisen in retikuloendothelialen Makrophagen zur Bekämpfung von 
Infektionen Der daraus resultierende Eisenmangel ist eine der 
Hauptverteidigungsstrategien des Wirts. Ein aktuelles Modell postuliert, dass Hepcidin 
der entscheidende Effektor dieser Antwort ist, da dessen Freisetzung durch 
Makrophaghen und Hepatozyten den Abbau von FPN bewirkt und somit zur 
Zurückhaltung des Eisens in Geweben führt. 
Das Ziel meines PhD Projektes war es neue zelluläre Regulatoren des hepcidin-
vermittelten Ferroportinabbaus, ein fundamentaler Prozess in der Aufrechterhaltung 
systematische Eisenhomeoestase, zu identifizieren. Dafür etablierte ich eine HeLa 
Zelllinie, die ein hFPN-Renilla Fusionsprotein exprimiert her. Diese Zelllinie wurde für 
einen Hochdurchsatz RNAi Screen, der auf Kinasen und verwandte Proteine abzielt 
verwendet. Der Screen identifizierte 71 von 779 getesteten Genen als mögliche 
Regulatoren FPN Proteinstabilität. 24 dieser Gene konnten in Validierungsexperimenten 
bestätigt werden. Interessanterweise, war der Effekt der meisten dieser validierten 
Kandidaten hepcidin-unabhängig Von den validierten Genen habe ich 14 Stück,  die mit 
Immunprozessen assoziert sind, für die weitere Charakterisierung in 
Knochenmarksmakrophagen von Mäusen (BMDMs) ausgewählt und fokussierte meine 
Analysen daraufhin auf den Toll-like Rezeptor 6 (TLR6). Ich untersuchte wie der TLR6 
Aktivierungssignalweg die Eisenregulierung im inflammatorischen Kontext moduliert. 
TLR2/6 Ligation durch das synthetische Lipoprotein, FSL1, von Mycoplasma löst eine 
starke Abbnahme von FPN mRNA- und Proteinexpression sowohl in BMDMs als auch 
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in der Leber und Milz von Mäusen aus. Interessanterweise Weise änderte sich die 
Hepcidinexpression nicht. Die Hepcidin unabhängige FPN Herunterregulierung war eine 
konservierte Antwort auf verschiedene microbielle Lipopeptide und deckte einen 
schnellen, Hepcidin unabhängigen Mechanismus zur Eisenrestriktion auf. Diese 
Resultate wurden durch C326S FPN Knock-in Mäuse, deren FPN resistent gegen 
Hepcidin ist, bestätigt. Diese Arbeit stellt die allgemein geltende Rolle von Hepcidin bei 
inflammatorischem Eisenmangel in Frage und legt nahe, dass die Hepcidin 
unabhängige FPN Herunterregulierung der erste, sehr schnelle Schritt in der 
Zurückhaltung von Eisen vor Pathogenen darstellen könnte. 
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ABBREVIATIONS 
General abbreviations 
 
% per cent 
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g gram 
GDF15 growth differentiation factor 15 
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h hour 
H2O water 
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HJV hemojuvelin 
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IgG immunoglobulin G 
IL interleukin 
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IRIDA iron-refractory iron-deficiency anaemia 
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JAK Janus kinase  
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kDa kilo Dalton 
l liter 
LB Luria-Bertani 
LIP labile iron pool 
LPS lipopolysaccharide 
m mili 
M molar 
MAP mitogen-activated protein 
MEK1 MAPK/ERK kinase 1 
min minute 
mol mole 
mRNA messenger RNA 
MVB multivesicular bodies 
n nano 
NaCl Sodium chloride 
NFkB nuclear factor of kappa light polypeptide gene enhancer in B-cells 
NRAMP1 natural resistance-associated macrophage protein 1 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
Pen/Strep Penicillin/Streptomycin 
PI3K phosphoinositide 3-kinases 
PVDF polyvinylidene fluoride 
Rluc renilla luciferase 
RNA ribonucleic acid 
RNAi RNA interference 
rpm rotations per minute 
RPMI-1640 Roswell Park Memorial Institute-1640 
RT reverse transcription 
SD standard deviation 
SDS sodium dodecyl sulphate 
sec seconds 
SEM standard error of measurements 
siRNA small interfering RNA 
SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 
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STAT3 signal transducer and activator of transcription 3 
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TfR1 transferrin receptor 1 
TfR2 transferrin receptor 2 
TGFβ transforming growth factor-β 
TLR toll like receptor 
TMPRSS6 transmembrane protease, serine 6 
TNF tumor necrosis factor 
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V Volts 
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μ micro 
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1 INTRODUCTION 
1.1 Iron 
Iron (Fe) is the fourth most abundant element in the Earth’s crust and one of the 
essential elements for human life(1). It exists in a wide range of oxidation states, -2 
to +6, whereby the ferrous (Fe2+) and the ferric (Fe3+) states are the most common 
ones and  for its  ability to fluctuate between these two oxidation states it is 
indispensable for many biological reactions and life. Iron-containing enzymes and 
proteins are utilized from primitive archea to humans and are involved in  
processes, such as oxygen transport (e.g. hemoglobin), metabolic reactions (e.g. 
cytochromes) or iron transport (e.g. transferrin). Proteins can contain iron in 
prosthetic groups as iron—sulfur cluster, like several enzymes of the mitochondrial 
respiratory chain or as heme (2, 3), like myoglobin, the muscle oxygen storage 
protein. In addition elementary iron can also function as cofactor for enzymes such 
as ribonucleotide reductase which is essential for DNA synthesis. Although vital, its 
chemical reactivity as transition metal, renders free iron potentially dangerous by 
generating highly reactive free radicals that can mediate cell damage (4). Free Fe2+ 
ions in solution are known to trigger Fenton’s reaction Fe2+ +H2O2 → Fe
3+ + OH. + 
OH− which causes the production of highly reactive hydroxyl radicals able to 
mediate peroxidation of lipids and oxidation of protein and nucleic acids (5). 
 
1.2 Iron homeostatic control 
The association of iron with proteins neutralizes its potentially harmful effects and 
drives its crucial biological functions in the cells. However additional and tight 
cellular and systemic regulations have evolved to maintain a plasma iron 
concentration that ensures adequate supplies while preventing detrimental organ 
iron overload or deficiency. 
1.3 Cellular iron control 
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1.3.1 The journey of iron through the cell 
In the plasma iron circulates bound to transferrin (Tf), each molecule containing 
two specific high-affinity Fe3+ binding sites. Diferric transferrin binds to transferrin 
receptor 1 (TfR1) at the plasma membrane and triggers the invagination of clathrin-
coated endosomes (6). In acidificated endosomes conformational changes in both 
Tf and TfR1 promote the release of Fe3+ from transferrin. As ferric iron is not 
bioavailable, the ferrireductase activity of the STEAP (Six Transmembrane 
Epithelial Antigen of the Prostate) family of metalloproteinases mediates the 
reduction of Fe3+ to Fe2+ (7, 8). Fe2+ is then transferred to the cytoplasm by divalent 
metal transporter 1(DMT1) and apo-Tf and TfR1 are recycled to the cell surface. In 
addition to TfR1, a homologous protein, transferrin receptor-2 (TfR2) whose 
expression is restricted to hepatocytes, erythroid cells and duodenal crypt cells, 
can bind Tf, even though with lower affinity. Although predominant, Tf-dependent 
iron uptake is not the only mechanism mediating iron entry into cells. Several 
pathways for non-Tf bound iron have been described. For instance, in intestinal 
absorptive cells DMT1  mediates iron uptake after Fe3+ from the diet is reduced to 
Fe2+ by the cytochrome b-like ferrireductase (Dcytb) (9). Iron may also enter the 
cell via other iron-bound protein such as hemoglobin which is released by 
erythrocytes, especially during intravascular hemolysis. Hemoglobin binds to the 
acute phase protein haptoglobin forming a complex which is then removed from 
the plasma via the scavenger receptor CD163 mainly expressed on monocytes 
and macrophages (10). Iron in heme can also move into cytoplasm via heme 
transporters, such as heme carrier protein 1 (HCP1) identified in brush-border 
membrane of duodenal enterocytes (11) and the mammalian homolog heme 
responsive gene 1 (HRG-1), a transmembrane heme permease in C. elegans, 
which is mainly expressed in macrophages and transports heme from the 
phagolysosome to the cytoplasm during erythrophagocytosis (12). The activity of 
these transporters is coupled to the activity of the cytoplasmic heme oxygenase 
(HO) that extracts iron from heme. 
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Once in the cell, most of the iron is directed towards mitochondria where is used 
for Fe-s cluster biogenesis and heme synthesis in erythroblasts. Approximately 
only 5% of cellular iron is maintained as redox-active iron source for immediate 
metabolic needs producing the so called labile iron pool (LIP). The portion that is 
not required is sequestered and stored by ferritin, a multimeric protein consisting of 
24 light and heavy chain subunits. For its enzymatic properties ferritin can convert 
Fe2+ in Fe3+ and store up to 4500 iron atoms (13) achieving both iron detoxification 
and storage. 
Unlike iron uptake, which can be mediated by several mechanisms, only one iron 
export protein is known at present: ferroportin (FPN) which is the only iron exporter 
in vertebrates (14-16) mediating iron release mainly from duodenal enterocytes, 
macrophages, hepatocytes, placental syncytiotrophoblasts and cells of the central 
nervous system. Iron exit requires its oxidation to Fe3+ which is performed by the 
multicopper oxidases ceruloplasmin (17) and its intestinal homolog hephaestin 
which work in concert with FPN to load iron onto Tf for transport in the 
bloodstream. The function of multicopper oxidases prevents the generation of 
oxygen radicals that are otherwise produced by spontaneous oxidation of iron. 
Furthermore thanks to their high affinity for oxygen they effectively increase the 
rate of oxidation which is particularly important, for example, under low oxygen 
tension conditions. 
1.3.2 IRE/IRP regulatory network 
The coordination between iron uptake, utilization, storage and export is maintained 
through the regulation of iron-related genes at several levels, from transcription to 
translation. In particular, posttranscriptional regulation has been well characterized 
and plays a key role in modulating cell response to iron levels. It relies on the 
trans-acting iron regulatory proteins (IRPs) and their interaction with iron-
responsive elements (IREs) (18), conserved motifs in the mRNA of iron-related 
genes. Single IRE is located in the 5’ untranslated regions (UTRs) as in FPN and 
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ferritin transcripts and inhibits the translation process upon IRP binding (19). 
Conversely, multiple IREs placed in the 3’ UTR serve to stabilize the mRNA, as for 
TfR1 transcript. IRPs exist in two isoforms, IRP1 and IRP2 which bind to IREs in 
response to the cellular labile iron pool. When iron levels are high IRP1 switches 
from its active RNA binding form to an Fe-s cluster containing cytoplasmic 
aconitase that interconverts citrate in isocitrate, at the same time IPR2 is targeted 
for proteosomal degradation (20). On the other hand, in iron-depleted cells IRP1 is 
activated as RNA binding protein and IRP2 is stabilized, becoming both fully active 
to inhibit, for example, the translation of FPN, reducing iron exit and stabilize TfR1 
mRNA, increasing iron uptake, both effects counteracting iron deficiency (Figure 
1.1). The importance of appropriate IRP regulation has been highlighted by several 
mouse models. The lack of both proteins determines early death of mouse 
embryos (21, 22). IRP1-/- mice misregulate iron metabolism only in the kidney and 
brown fat, whereas IRP2-/- mice show altered expression of target proteins in all 
tissues (22) and develop microcytosis (23), suggesting that the activity of these two 
proteins is only partially redundant. Furthermore, conditional expression of a 
constitutively active IRP1 was reported to cause abnormal body iron distribution 
and impaired erythropoiesis (24), confirming the essential role of the IRP/IRE 
regulatory network even in the systemic iron homeostasis. Importantly, the IRP/IRE 
system seems also to extend beyond the well-studied iron metabolism targets, as 
suggested by the identification of novel IRP targets involved, for example, in the 
cell cycle regulation and oxygen metabolism (25). 
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Hentze et al., Cell, 2010  
Figure 1.1 Cellular iron regulation via IRP1/2 system. In iron-replete cells IRP1 is inactivated by 
conversion into the Fe-S cluster containing aconitase, while IRP2 is targeted for proteosonal 
degradation.  Low cellular iron levels activate IRP1 and stabilize IRP2 allowing the binding to the 
IREs located in the 5’ UTRs which causes translation inhibition and in the 3’ UTRs which causes 
mRNA stabilization. Translation repression applies, for example, to ferroportin and ferritin 
transcripts, ultimately reducing iron storage and export, while mRNA stabilization rises the 
expression of TfR1, increasing iron uptake. Both effects counterbalance the cellular iron deficiency. 
 
1.4 Systemic iron regulation 
The human body approximately contains 3-4 grams iron, mostly (around 65%) 
present in haemoglobin of erythrocytes. The cells of all tissues contain iron in iron-
containing proteins required for the energy metabolism and cellular proliferation, 
however the liver and the spleen are the major reserve organs for iron which is 
stored in macrophages and hepatocytes. 
The distribution and the mobilization of iron between distinct body compartments 
involve several organs and tissues (Figure 1.2). Under normal circumstances only 
1-2 mg dietary iron per day is absorbed in the proximal duodenum and released 
into the blood bound to the iron-transporter protein Tf. Most of this iron is taken up 
by erythrocyte precursors in the bone marrow and utilized for haemoglobin 
synthesis. About 70% of circulating body iron is in red blood cells and is recycled 
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by the macrophages of the reticuloendothelial system that remove old or damaged 
erythrocytes from the bloodstream.  
Iron absorption normally balances small iron losses which mainly derive from 
desquamation of epithelium or minor bleeding, thus the recycling system is mainly 
responsible for the plasma iron turnover and its homeostatic control. 
The coordination of iron flows from tissues to circulation needs to be tightly 
maintained to prevent iron accumulation or deprivation which ultimately result in 
diseases.  
 
Figure 1.2 Systemic iron regulation. Different cell types and tissues coordinate iron homeostasis. 
Dietary iron enters the body through intestinal mucosal cells and is then bound to plasma transferrin 
to be delivered to cells. Only 1-2 mg of iron are normally absorbed and are sufficient to balance 
physiological minor iron losses. Most of the iron that enters the plasma comes from macrophages 
that recycle iron from senescent or damaged erythrocytes. In turn, the majority of this iron is used 
for hemoglobin synthesis by erythrocyte precursors in the bone marrow to sustain the erythrocyte 
turnover. When iron accumulates, it is deposited in parenchymal tissues such as the liver which is 
the main storage compartment. The release and the distribution of iron in the body are controlled 
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via the binding of the liver hormone hepcidin to the iron exporter FPN (mainly expressed in 
enterocytes, macrophages and hepatocytes) which cause FPN endocytosis and proteolysis.  
 
1.4.1 The hepcidin/ferroportin axis 
The maintenance of iron homeostasis critically depends on the interaction between 
the liver peptide hormone hepcidin and the cell surface iron exporter FPN (26, 27). 
Hepcidin expression in the liver is regulated by different stimuli, such as iron 
availability, inflammation and hypoxia (26). It binds to FPN at the plasma 
membrane of enterocytes, macrophages and hepatocytes inducing its 
internalization and degradation, resulting in decreasing iron export and cellular iron 
retention (28). Thus the hepcidin/FPN circuitry controls dietary iron absorption, iron 
release from macrophages, mobilization of iron from hepatic stores and iron 
transfer across the placenta (Figure 1.3). 
 
Figure 1.3 The hepcidin/FPN axis. Hepcidin is a 25 amino acids peptide produced by the liver. 
FPN is a transmembrane protein mainly expressed in hepatocytes, macrophages and enterocytes 
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and it is the only known iron exporter. Hepcidin binds to FPN at the plasma membrane and induces 
its internalization and degradation. When hepcidin concentration is low, FPN is fully active and iron 
enters plasma where it is loaded onto transferrin for transport (Tf-Fe3+), on the other hand when 
hepcidin concentration is high, FPN is internalized and iron is trapped in enterocytes, macrophages 
and hepatocytes.  
 
1.5 Regulation of hepcidin expression 
Hepcidin discovery dates from 2000 and was made in human blood ultrafiltrate and 
in urine (29, 30). It was identified as cysteine-rich antimicrobial peptide even 
though it shows only modest antimicrobial activity in vitro at very high 
concentration. Although the relevance of its antimicrobial function in vivo remains 
unclear, its role in iron homeostasis is very well established. Hepcidin levels are 
rapidly modulated in consequence of several stimuli and dysregulation of its 
synthesis has severe implications in a large spectrum of iron disorders. 
1.5.1 Hepcidin regulation by iron 
Hepcidin appears to be a principal regulator of systemic iron homeostasis. In turn 
its synthesis is regulated by plasma iron concentration and iron stores, primarily at 
transcriptional level. Iron supplementation in the diet induces hepcidin mRNA 
increase in mice (31) while low iron diet leads to the opposite outcome. The core 
components of this regulatory mechanism are the bone morphogenetic protein 
receptor (BMPR) and the SMAD signalling proteins. Hepatic iron level are sensed 
through increased production of bone morphogenetic proteins (BMP) which belong 
to the transforming growth factor-β (TGF-β) superfamily and bind to BMP Type I 
and Type II serine threonine kinase receptors. Several BMP ligands can induce 
hepcidin expression in cultured cells, however BMP6 appears to be the key 
endogenous regulator of hepcidin in vivo (32, 33). Its production increases when 
hepatic iron levels are high, suggesting that this may represent the signal reflecting 
iron store amounts. The activation of BMPR upon BMP binding causes the 
phosphorylation of intracellular receptor associated SMAD proteins (R-SMADs) 
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which together with the common mediator SMAD4 translocate to the hepatocyte 
nucleus to induce hepcidin transcription. Consistently, it has been shown that 
phosphorylation of R-SMADs in the liver increases with iron enrichment in the diet 
and mildly decreases with iron restriction (34). Hepatic BMP signalling is 
augmented by the iron-specific BMPR coreceptor hemojuvelin (HJV) to induce 
hepcidin (35). HJV in turn is regulated by the liver-specific protease matriptase2 
(also called TMPRSS6) which, stabilized by iron deficiency, cleaves and 
inactivates HJV (36) negatively regulating hepcidin expression (Figure 1.4). 
Attenuation of hepcidin activation also comes from iron-stimulated expression of 
other SMAD proteins, such as SMAD6 and SMAD7 that have been described to 
mediate a negative  feedback regulation (37, 38). 
Extracellular iron concentration is sensed by the interaction of transferrin bound 
iron (Tf-Fe) and the “the iron sensing complex” composed of TfR1, TfR2, the 
human hemochromatosis protein (HFE) and HJV (39) which physically interact on 
the cell surface of hepatocytes. The interaction of HFE with TfR1 or TfR2 shifts 
according to Tf-Fe concentration (40). Under iron-rich conditions HFE is released 
from TfR1 (which has higher affinity to transferrin-bound iron) and becomes 
available for interaction with TfR2 enhancing SMAD signalling and promoting 
hepcidin up regulation (Figure 1.4). Consistent with this model, mice lacking HFE 
or TfR2 were shown to have an attenuated BMP signalling (39) while mice 
expressing a mutated form of TfR1 which constitutively binds HFE exhibited low 
hepcidin levels and developed hemochromatosis (41). Although the importance of 
these proteins for hepcidin regulation is supported by study of patients who carry 
mutations in the related genes, the exact regulatory mechanisms of their 
interaction is not yet understood. 
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Coyne, Kidney International, 2011 
Figure 1.4 Hepcidin expression regulations by iron and inflammation. The activation of BMP 
receptor after BMP binding (e.g. BMP6) induces hepcidin transcription via the SMAD signalling 
pathway. Under iron sufficiency conditions, transferrin-bound iron binds to TFR1 and displaces HFE 
which becomes available for interaction with TFR2. HFE-TFR2 interaction enhances hepcidin 
transcription either directly or in concert with the BMP/SMAD signalling pathway. Under iron 
deficiency conditions hepcidin transcription is impaired via the protease TMPRSS6 which cleaves 
the BMPR coreceptor HJV, releasing soluble HJV (sHJV) which negatively regulates BMP/SMAD 
signalling. Inflammation induces IL6 production by macrophages. IL6 binds to its receptor and 
triggers Janus kinase (JAK) to activate STAT3 signalling which ultimately leads to hepcidin 
transcription induction. 
1.5.2 Hepcidin regulation by hypoxia 
Hepcidin is inhibited by hypoxia by several proposed mechanisms. In particular 
oxygen deficiency stimulates erythropoiesis via erythropoietin (EPO) production 
and consequently increases iron requirements, leading to hepcidin reduction. 
Consistently, in humans hypoxia caused by high altitude results in lower hepcidin 
levels (42, 43). The hypoxia-responsive system involves hypoxia inducible factors 
(HIF-1 and HIF-2), which are stabilized under hypoxic condition and regulate the 
transcription of several iron-related genes. It was reported that HIF complexes may 
directly repress hepcidin promoter activity both in cells and in murine livers (44, 
45). However experiments with transgenic mice lacking or constitutively expressing 
HIF2α indicate that hepcidin regulation occurs through EPO-mediated increased 
erythropoiesis rather than via direct effects on hepcidin promoter (46). Hypoxic 
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responsive elements were also found in the TMPRSS6 promoter, suggesting that 
the increased transcription of this protein represents an additional mechanism to 
inhibit hepcidin (47) in such conditions. 
1.5.3 Hepcidin regulation by erythroid factors 
The synthesis of new red blood cells requires about 20 mg of iron every day. 
Increased demand of iron for erythropoiesis (in consequence of hemolysis or 
phlebotomy) suppresses hepcidin (48) to rise iron availability. The EPO produced 
by the kidney to stimulate erythropoiesis, for example under hypoxic conditions, 
was reported to directly mediate hepcidin inhibition in hepatic cells (49). However 
in bone marrow-depleted mice neither EPO treatment nor hemolysis was 
demonstrated to alter hepcidin levels, suggesting that this compartment is actually 
essential for hepcidin modulation (50). Subsequent studies have identified two 
soluble factors, members of TGF-β superfamily, growth and differentiation factor 15 
(GDF15) and twisted gastrulation homolog 1 (TWSG1) as “erythroid regulators” 
(51, 52) accounting for hepcidin suppression. Although TWSG1 was shown to 
inhibit hepcidin in vitro by altering the BMP signalling, the mode of action for 
GDF15 remains as unclear as the cross-talk between erythroid signals and the 
BMPs. Very recent is the identification of an erythroid factor made by erythroblasts 
named “erythroferrone” (Erfe) whose expression was proven to increase in the 
bone marrow and the spleen of mice after phlebotomy or EPO stimulation(53). This 
response preceded the expected hepcidin reduction which was prevented in Erfe 
knock-out mice. Furthermore injection of recombinant Erfe were demonstrated to 
reduce hepcidin expression in wild type mice while the addition of the supernatant 
of HEK293T cells overexpressing Erfe significantly decreased hepcidin expression 
in murine hepatocytes. These lines of evidence and the observation that Erfe 
mRNA levels are increased in mouse model of β-thalassemia, suggest that this is 
the long-sought erythroid factor responsible for hepcidin suppression which may 
contribute to the pathogenesis of iron-loading anemia. 
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1.5.4 Hepcidin regulation by inflammation 
Iron is a growth factor for invading pathogens. As defence strategy circulating iron 
levels are reduced during infection leading to hypoferremia commonly associated 
to infections and inflammatory conditions. Numerous studies have demonstrated 
that inflammation modifies the expression of several iron-related genes, including 
hepcidin. Hepcidin induction by inflammatory stimuli was reported by several 
publications, all corroborating its crucial role in setting the inflammation-mediated 
hypoferremia (54-56). One of the most common mouse models for acute 
inflammation utilizes lipopolysaccharide (LPS) injection. This Gram negative 
bacterial membrane constituent is recognized by a member of Toll like receptor 
family, TLR4 mainly expressed in macrophages and dendritic cells where it initiates 
the inflammatory response. Intraperitoneal injection of LPS results in hepatic 
hepcidin induction which mediates the reduction of circulating iron by causing the 
degradation of ferroportin (57). Murine primary hepatocytes were shown to 
increase hepcidin expression upon TLRs ligand stimulation (58), however the 
expression of TLRs, and in particular of TLR4, in this cell type is subjected to 
controversy (59) (60) and it is possible that such response is rather mediated by 
macrophage contamination of the cell preparation. Hepcidin up regulation was 
demonstrated also in macrophages and neutrophils exposed to LPS, Gram 
negative and Gram positive bacteria suggesting that hepcidin release from myeloid 
cells contributes to restrict iron access to pathogens in infection microenvironment 
(57, 61). Among inflammatory cytokines, interleukin-6 (IL-6) seems to be a critical 
component of hepcidin activation in hepatocytes as reported by in vivo and in vitro 
data (55, 58). IL-6 binding to its receptors (gp80 and gp130) triggers Janus kinase 
2 (JAK2) to phosphorylate the signal transducer and activator of transcription 
(STAT)3 transcription factor which in turn activates the hepcidin promoter through 
its STAT3 binding motif (62-64) (Figure 1.4). However distinct reports have 
indicated that other cytokines, like IL-1 and IL-22 (65, 66) might be involved in 
hepcidin stimulation under inflammatory conditions. Interestingly, there appears to 
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be crosstalk between JAK/STAT3 pathway and the BMP pathway to mediate 
hepcidin activation as suggested by liver specific SMAD4 knockout mice which fail 
to induce hepcidin and develop hypoferremia upon IL-6 injection (67). Moreover 
BMP inhibitors were reported to block IL6-mediated hepcidin transcription in vitro 
(68) and injection of LPS in wild type mice has revealed a role of activinB (a 
member of TGF-β superfamily) in inducing hepcidin through SMAD1/5/8 signalling 
pathway (69). The involvement of the iron-related BMP signalling has been 
additionally supported by evidence in HFE and TFR2 knock-out mice which failed 
to mount a normal hepcidin response following LPS injection (70, 71) and by the 
identification of BMP-responsive elements in the hepcidin promoter important for 
IL-6 mediated response (72). 
 
1.6 Regulation of ferroportin expression 
Ferroportin (FPN), also known as SLC40A1, Ireg1, MTP1 and HFE4 was firstly 
identified as an iron exporter in enterocytes by three independent groups in 2000 
(14-16) . It appears to be the sole member of the SLC40 transporter family and is 
highly conserved among mammals with 90-95% homology among human, mouse 
and rat orthologs. FPN-deficient mice were demonstrated to accumulate iron in 
enterocytes, macrophages and hepatocytes shortly after birth, consistent with the 
essential role of FPN in the iron export of these tissues (73). The human SLC40A1 
gene encodes for a 570 amino acids protein which was proposed to assemble in 
12 putative transmembrane domains (74, 75). Controversial data were reported 
about its quaternary structure and it remains unclear whether it is a monomer (75-
77) or a dimer (78, 79). FPN is highly expressed in cells and tissues playing a 
critical role in systemic iron homeostasis, such as placenta and intestine 
responsible for iron absorption and transfer, and macrophages and hepatocytes, 
major sites of iron recycling. Expression of FPN also protects cells from 
manganese (80) and zinc (81) toxicity, suggesting that it can mediate the export of 
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other transition metals. While hepcidin expression is only known to be regulated at 
transcriptional level, several levels of control characterize FPN regulation. 
1.6.1 Ferroportin transcriptional regulation 
Transcriptional regulation of FPN was first shown following  erythrophagocytosis in 
the J774 macrophage cell line (82) and bone marrow derived macrophages (83, 
84). The degradation product of hemoglobin, heme, transcriptionally co-regulates 
heme oxygenase 1(HO1) (the enzyme that catalyzes heme degradation) and FPN, 
accelerating iron extraction from heme and the recycle of iron into the plasma. It 
has been proposed that while the protoporphyrin ring of heme is sufficient to 
increase FPN transcription in an iron-independent manner (85), the iron release 
from the heme moiety controls FPN post transcriptionally (84). Molecular insights 
were obatained with the identification of the transcriptional repressor Btb And Cnc 
Homology 1 (Bach1) as sensor of cellular heme levels. It antagonizes the activity of 
small Maf proteins (sMAF) that bind Maf recognition element (MAREs) in HO1 and 
FPN promoters to promote transcription. Heme binding induces Bach1 dissociation 
from sMAF and also stabilizes the Nuclear Factor Erythroid 2-like (NRF2) which 
binds to sMAF to enhance gene transcription utilizing specific forms of MAREs 
called Antioxidant Response Elements (ARE). MARE/ARE enhancer elements 
were identified at position -7007/-7016 of FPN promoter. Mutations of these 
elements were shown to abrogate transcription in reporter constructs (85).  
Increased erythropoiesis in hypoxic conditions while reduces hepcidin, also 
induces FPN mRNA levels. The stabilization of HIFs factors and in particular of 
HIF2α seems to directly activate FPN expression as suggested by the FPN 
transcription reduction following the intestine specific deletion of HIF2α (86) and by 
chromatin immunoprecipitation studies showing HIF2α binding to FPN promoter 
region in murine duodenum. Furthermore HIF-responsive elements (HREs) were 
identified in the FPN promoter whose mutations prevented FPN up regulation in 
response to low oxygen (87). 
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Direct induction of FPN transcription in macrophages is additionally caused by iron 
and other transition metals such as copper, zinc and cadmium (81, 88, 89). 
However in case of iron-induction, the relevant transcription factor has not been yet 
identified. For zinc and cadmium the molecular mechanism is clearer and involves 
the binding of the Metal Transcription Factor 1 (MTF-1) on two Metal Responsive 
Elements (MREs) sequences in the FPN promoter (81). 
Reduction in FPN transcription occurs during inflammation. LPS stimulation 
triggers FPN expression down regulation (57, 61, 90) in the spleen and in the liver 
to rapidly reduce iron availability for pathogens. It has been proposed that this 
effect is independent of specific cytokines, as mice lacking IL-6, TNFα or IL-1 were 
shown to retain the hypoferremic response and reduce FPN mRNA level upon LPS 
injection (57). However the cytokine contribution remains controversial, as it was 
also reported that TNFα mediated hypoferremia during the early inflammatory 
response by regulating the expression of FPN in macrophages (91). The 
importance of FPN function during infection is also supported by the finding that 
macrophages isolated from mice carrying a heterozygous loss-of-function mutation 
in FPN, exhibit increased susceptibility to intracellular bacterial growth (92). 
Nevertheless, little is still known about the molecular players responsible for FPN 
transcription in the inflammatory context and more work is needed to clarify its role 
in the immune response. 
1.6.2 Ferroportin post transcriptional regulation 
At the post-transcriptional level FPN is regulated via the IRE/IRP system. Similar to 
other iron-related genes, FPN mRNA contains an iron responsive element (IRE) in 
its 5’ untranslated region (UTR). As described in paragraph 1.3.2 in low iron 
conditions, the iron regulatory protein IRP binds the IRE element blocking the 
mRNA translation. On the other hand, when iron levels are restored, the 
inactivation of the IRPs allows the FPN mRNA translation. This mechanism 
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protects cells both from excessive iron depletion in case of low intracellular iron 
and from the toxicity that can derive from an excessive iron accumulation (93).  
Erythroid cells and duodenal enterocytes additionally express a FPN transcript 
variant which lacks the 5’-IRE, termed FPNB. This transcript is insensitive to iron 
regulation but keeps unaltered the open reading frame producing a protein that is 
functional but remains responsive to hepcidin. FPNB is produced from an alternate 
promoter located upstream of the canonical one, and is subjected alternative 
splicing of the 5’-UTR sequence (94). This form accounts for 25% of total FPN 
mRNA in the duodenum where it supports iron export even under conditions of iron 
deficiency. Much higher levels are present in erythroblasts which keep 
responsiveness to systemic iron deficiency via hepcidin regulation (95). 
1.6.3 Ferroportin post translational regulation 
FPN post translational regulation mainly is mediated by hepcidin activity. As 
described above (paragraph 1.4.1) hepcidin binding to FPN induces its 
internalization and degradation modulating the amount of iron exported. This 
explains both recessive iron overload disorders resulting from decreased hepcidin 
production and iron deficiency disorders resulting from increased hepcidin levels. 
Hepcidin was shown to induce FPN loss in cultured macrophages and hepatocytes 
(96) while In vivo lines of evidence came from hepcidin knockout mice which were 
reported to exhibit increased level of FPN in duodenum, spleen and liver. 
The mechanism underling the ferroportin internalization and degradation has been 
deeply investigated since its identification. Several publications have supported a 
model according to which hepcidin binding to FPN causes phosphorylation of two 
adjacent tyrosines (302, 303) in a cytoplasmic domain of FPN which triggers its 
internalization by clathrin-coated pits. Ubiquitination then targets FPN for 
degradation in lysosomes through the multivesicular bodies (MVB) pathway 
requiring the participation of the ESCRT complexes (97) (Figure 1.5). The Janus 
Kinase 2 was then reported to initiate the process (98). However this model has 
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been lately re-examined by two publications showing that neither JAK2 nor 
phosphorylation of FPN residues 302 and 303 is indeed required for hepcidin-
mediated internalization and that ubiquitination is actually the key molecular signal 
for FPN endocytosis (99, 100). 
Besides, the presence of endogenous FPN in raft domains demonstrated in 
macrophages (101) has questioned the proposed clathrin-dependent FPN 
internalization, revealing the existence of new possible cellular pathways involved 
in hepcidin-mediated FPN endocytosis. 
 
De Domenico et al., Molecular Biology of the Cell, 2007 
Figure 1.5 First proposed model of hepcidin-mediated ferroportin internalization and 
degradation. 
 
1.7 Ferroportin and hepcidin regulation by miRNAs 
Over the last years several lines of evidence implicating small non-coding RNAs in 
iron metabolism have been accumulated and reviewed (102) adding a further 
regulatory mechanism to the post transcriptional regulation of FPN and other iron-
related genes. MicroRNAs are a class of small non-coding RNA which regulate 
gene expression via base-pairing with complementary sequences 
within mRNA molecules (103). At the cellular level iron homeostasis seem to be 
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regulated by miRNAs at multiple steps from iron acquisition to export. Modulation 
of cellular iron export by FPN was recently shown in association with miR-485-3 
whose overexpression leaded to increased cellular ferritin levels by repressing 
FPN expression. Conversely, both inhibition of miR-485-3p activity and mutation of 
the miR-485-3p target sites on the FPN 3'UTR mediated opposite effects (104). 
Together, these findings support a model that includes both IRPs and microRNAs 
as iron-responsive post-transcriptional regulators of FPN. 
Liver-specific miR-122 provides an example of miRNAs-mediated iron regulation at 
systemic level (105). Depletion of miR-122 in mice was shown to lead to systemic 
iron deficiency and mildly impaired hematopoiesis associated with increased 
mRNA level of HFE, HJV, hepcidin and BMPR1A. In particular it was proven that 
HFE and HJV are directly targeted by miR-122 which affects hepcidin expression 
in the liver and causes iron reduction in the plasma. 
 
1.8 Iron related disorders 
The study of molecular mechanisms underlying genetic iron disorders has been 
very helpful in deciphering the molecular mechanisms controlling systemic and 
cellular iron homeostasis. Major iron disorders can be classified in iron overload 
and iron deficiency diseases due to iron excess and iron scarcity, respectively. The 
key factor in many of these conditions is hepcidin misregulation and the resulting 
imbalance of the hepcidin/FPN regulatory system. 
1.8.1 Iron overload diseases 
Hereditary Hemochromatosis (HH) is a primary iron overload disease. In HH 
patients, dietary iron absorption exceeds iron loss by approximately 3mg per day, 
resulting in excessive iron accumulation in several organs, in particular liver and 
pancreas. Iron overload generates oxidative stress damaging tissues. The most 
common consequences are hepatomegaly, liver cirrhosis, hepatocellular 
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carcinoma, diabetes mellitus, hypogonadism, cardiomyopathies and arthritis. If 
untreated, massive iron accumulation can be lethal (106, 107). 
HH is a genetically heterogeneous disease but all the mutations share the common 
effect of disrupting the hepcidin/FPN regulation, due to the lack of hepcidin 
synthesis or FPN functionality or to the lack of the hepcidin/FPN interaction. 
According to the gene involved in the pathogenesis, the clinical severity and the 
onset of the disease, HH has been divided in subtypes. HH type 1-3 is 
characterized by mutations in the iron-sensing machinery that result in an 
inappropriately low or absent hepcidin production in response to the increased 
systemic iron level. HH type I is caused by mutations in HFE (108-110) and is the 
most common form of the disease accounting for around 85% of cases. At least 32 
mutations of the HFE gene have been described, however the vast majority of 
patients with HH type 1 are homozygous for the C282Y mutation which leads to a 
misfolded, non-functional protein. Despite the high frequency of this missense 
mutation in the Caucasian population, this kind of HH shows low and variable 
penetrance. HH type II is a juvenile and more severe disorder characterized by 
early onset in childhood and caused by rare mutation in HJV (HFE2) (111-113) or 
hepcidin itself (114). The HH type III is another late-onset form of disease 
produced by mutations in TfR2 (115). These are all recessive forms of HH. The 
only genetically autosomal-dominant form derives from missense mutations in the 
FPN gene (116) causing two distinct alteration of its functions. 
Classical ferroportin disease is caused by loss of function mutations that lead 
incorrect targeting of the protein to the plasma membrane or to the production of 
an inactive iron transporter. Clinically, this disease is hallmarked by 
hyperferritinemia in presence of a normal to low transferrin saturation and by iron 
overload in specialized iron-exporting cells, such as the Kupffer cells of the liver 
and the splenic macrophages. Affected patients often do not tolerate phlebotomy 
since it rapidly results in very low transferrin saturation and anemia. (117) The 
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flatiron (ffe) mouse model carrying the SLC40A1-H32D mutation which causes an 
impaired ferroportin localization and activity fully recapitulates this disorder (118).  
A HH-like phenotype is caused by “gain of function” mutations that render FPN 
insensitive to hepcidin-mediated degradation. The clinical phenotype is hallmarked 
by hyperferritinemia and high transferrin saturation. The continuous and 
unregulated iron uptake provokes iron accumulation in hepatic cells while 
macrophages are iron depleted. This so called non classical ferroportin disease is 
rare and only a few mutations have been reported. Among these, the C326S/Y 
mutation has been well characterized in cell-based assays (76, 119) and a mouse 
model was generated (190). The cysteine 326 is located in the third extracellular 
loops of FPN and its free thiol group is necessary for the hepcidin binding. 
Mutations of this amino acid residue prevent the hepcidin/FPN interaction causing 
hemochromatosis (120). The non-classical ferroportin disease is the only member 
of the HH family which is associated with  increased hepcidin levels (121) thanks to 
the responsiveness of HFE/TfR2/HJV iron sensing machinery that is critical to 
maintain hepcidin synthesis. 
1.8.2 Iron deficiency diseases 
Iron deficiency is not always associated with anemia which occurs, by definition,   
when hemoglobin levels are below 13 g/dl in men and 12 g/dl in women. 
Decreased iron stores without anemia determine latent iron deficiency conditions 
characterized by decreased ferritin level in an early phase and soluble high 
transferrin receptor levels (released from erythroid cells) in a later phase. However 
more common are the subtypes of iron deficiency linked to anemia. 
1.8.2.1 Iron deficiency anemia 
Iron deficiency anemia (IDA) represents half of all anemia cases worldwide and is 
characterized by low hemoglobin levels as a result of depleted iron stores. It is 
caused by insufficient dietary intake and absorption or it is consequent of increased 
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iron needs, for example in pregnancy or in case of blood loss. Oral iron 
supplementation or, in worse cases, intravenous iron administration are usually 
sufficient to revert the clinical phenotype. More severe are subtypes of anemia 
linked to ineffective erythropoiesis and genetic alterations. 
1.8.2.2 Iron-loading anemias 
Iron-loading anemias are usually associated with red blood cell disorders, such as 
thalassemia. In this disorder it was observed (122-124) that hepcidin levels did not 
correlate with liver or systemic iron load but with altered erythropoietic parameters. 
Increased and ineffective erythropoiesis (or hemolysis) augments iron demand and 
leads to hepcidin suppression despite progressive iron overload in the body. Low 
hepcidin allows iron hyperabsorption and maldistribution, exacerbating systemic 
iron overload and iron accumulation in the organs. This finding also suggests that 
erythropoietic factors have a dominant effect over iron on hepcidin regulation, as 
additionally confirmed in sickle cell anemia (125) and myelodysplastic syndrome 
(126). 
1.8.2.3 Iron refractory-iron deficiency anemia 
Loss-of-function mutations in hepatic protease TMPRSS6 are known to cause iron 
–refractory iron deficiency anemia (IRIDA) (127).  In this genetic disorder the 
negative regulation of HJV, mediated by TMPRSS6 under iron deficiency 
conditions (Figure 1.4), is lost, leading to accumulation of HJV, dysregulated 
BMP/SMAD signalling, and consequently, inappropriately high levels of hepcidin. 
This ultimately causes uncontrolled FPN degradation due to high hepcidin loads 
and, therefore, to iron deficiency anemia which is unresponsive to oral iron therapy 
and parental iron treatment, as iron absorption and release from store are 
irreversibly impaired by inappropriate hepcidin expression. 
1.8.2.4 Anemia of inflammation 
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Anemia of chronic disease (ACD), also known as anemia of inflammation is the 
most prevalent anemia subtype. It is associated with inflammatory conditions, such 
as cancer, infections, rheumatoid arthritis and chronic kidney disease. It is 
characterized by a multifactorial etiology, involving immune cell activation and 
massive inflammatory cytokine production. ACD is a normocytic anemia with 
blunted erythropoiesis (128). Despite decreased circulating iron (low serum iron) 
and iron binding capacity (low transferrin saturation), macrophages retain and 
accumulate iron impairing mobilization of iron from stores (129). The main cause 
for iron deficiency is attributed to excess levels of hepcidin, whose synthesis is 
induced by inflammatory cytokines, as indicated by several reports (130-132) and 
as described in 1.5.4. The treatment options for ACD include blood transfusion, 
iron administration and erythropoiesis-stimulating agents (ESAs). However 
different adverse effects are related to all of these treatments. For example, tumor 
progression seems to be accelerated by ESAs treatment in cancer and 
myelosuppressive therapy (133, 134). Toxic effects are expected also from long-
term intravenous iron therapy. For instance excess iron may increase the risk of 
infection, as iron represents a growth factor for pathogens. Thus, many studies are 
now focused on identifying alternative treatments targeting the main cause of this 
pathophysiology: hepcidin excess and FPN activity reduction. Novel strategies to 
decrease hepcidin levels include hepcidin antagonists (anti-hepcidin antibody, 
short interference RNA against hepcidin, engineered lipocalins as hepcidin binding 
proteins) and hepcidin inhibitors which target the signaling pathways mediating 
hepcidin synthesis (BMP6-HJV-SMAD and IL6-STAT3) (68, 135). In addition 
several screening approaches aim at identifying new molecules which may work as 
ferroportin agonists and stabilizers to correct iron deficiency (136). However the 
safety and the efficacy of all these treatments for humans remain to be proven. 
Finally, understanding the hepcidin-independent FPN transcription response during 
inflammation, whose molecular mechanisms are still poorly understood, will help to 
design and develop novel and more therapeutic approaches for this widespread 
condition.  
_______________________________________________________Introduction 
33 
1.9 Aim of the study  
Hepcidin-mediated FPN regulation plays a pivotal role in controlling and 
maintaining iron homeostasis. At the beginning of this project few molecular details 
of this process had been. Thus, the specific aim of this study was to identify genes 
and cellular processes that control hepcidin-induced FPN internalization to better 
understand this pathway and find novel regulators suitable for pharmacological 
manipulation. I expected that this would establish the basis for novel treatment 
options of iron-related disorders in which the hepcidin/ferroportin circuitry is altered.   
To reach this aim a large-scale RNAi screening approach was chosen to 
investigate the function of kinases and other related signalling molecules in FPN 
regulation. 
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2 EXPERIMENTAL PROCEDURES 
2.1 Materials 
2.1.1 Frequently used reagents and chemicals 
Glycine, Tris-(hydroxymethyl)-methylamine (Tris), sodium chloride (NaCl), 
methanol, ethanol, isopropanol and sodium dodecyl sulphate (SDS), 
deoxyribonucleotide triphosphates (dNTPs) were from Carl Roth GMBH 
(Karlsruhe, Germany). Triton X100 was obtained from Fluka Analytical (Munich, 
Germany). Lysis Buffer and substrates for renilla luciferase assay were from 
Promega (Madison, WI, US). Dulbecco’s Modified Eagle Medium (DMEM), Roswell 
Park Memorial Institute-1640 (RPMI-1640), Opti-MEM®, fetal calf serum (FCS), 
sodium pyruvate and penicillin/streptomycin (Pen/Strep) were all from Gibco BRL 
div. of Invitrogen (Karlsruhe, Germany), Dulbecco’s phosphate buffered saline 
(PBS) from PAA laboratories (Pasching, Austria). Hyclone fetal Bovine serum 
defined for bone marrow derived macrophages was from Thermo Scientific and 
macrophage colony-stimulating factor from mouse was obtained from Sigma-
Aldrich. Random primers were purchased from Invitrogen (Karlsruhe, Germany).  
Cell culture multi-well plates, dishes, flasks, tubes and falcons were obtained from 
Sarstedt (Nümbrecht, Germany) or Greiner Bio-One (Frickenhausen, Germany). 
PVDF membranes were from GE Healthcare (Little Chalfont, UK).  
 
2.1.2 Transfection reagents 
Listed below in Table 2.1 are the transfection reagents that were used in this work. 
Unless stated otherwise, the manufacturer’s recommendations were followed. 
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Application Name Supplier 
Plasmid DNA 
transfection 
(generation of cell lines) 
TransIT®-LT1 
Transfection Reagent 
Mirus Bio  
 
  
 
 
Reverse siRNA 
transfection (Hela) 
Direct siRNA  
transfection (BMDMs) 
Dharmafect1 
Transfection Reagent 
Lipofectamine 
RNAiMAX 
Dharmacon 
 
Life Technologies  
   
Table 2.1 Transfection reagents. 
2.1.3 Enzymes, recombinant protein and antibodies 
The restriction enzymes, T4 DNA Ligase, Calf Intestinal Alkaline Phosphatase 
(CIAP), DNA polymerase I were obtained from New England Biolabs (NEB) 
(Ipswich, MA, USA) and were used according to the NEB guidelines. The reverse 
transcriptase, RevertAid™ H Minus M-MuLV, was from MBI Fermentas (Burlington, 
Ontario, Canada).  
Recombinant human hepcidin/LEAP-1 was obtained from Peptides International, 
Inc. (US). Recombinant murine IL6 and IL1β were purchased from R&D Systems 
(Wiesbaden, Germany), recombinant mouse Tumor Necrosis Factor-α was from 
Life Technologies.   
Primary monoclonal anti-GFP was obtained from Roche (Mannheim, Germany). 
Primary rabbit anti-mouse MTP11 IgG and anti-rat HFE IgG were purchased from 
Alpha Diagnostic (San Antonio, US). Primary rabbit anti-Tet Repressor was from 
Sigma-Aldrich as well as all the secondary anti-mouse and anti-rabbit IgG 
peroxidase conjugate antibodies. Primary anti-phospho-Src Family(Tyr416) 
antibody and anti-phospho-Akt(Ser473) antibody were purchased from Cell 
Signaling Technology.  
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2.1.4 Buffer and solutions 
All buffers and solutions used in this study are listed in Table 2.2. 
Buffers and Solutions Preparation 
  
Antibiotic solutions (1000x) 100 mg/ml ampicillin in H2O 
DNA loading buffer (6x) 0.9% (w/v) bromophenol blue 
 60% (v/v) glycerol 
 60 mM EDTA pH 8.0 
Luria-Bertani (LB) agar 
(autoclaved) 
15 g/l Bacto™ Agar in LB broth 
LB broth (autoclaved) 10 g/l Bacto™ Tryptone 
 5 g/l Bacto™ Yeast extract 
 5 g/l NaCl 
 pH 7.6 (adjusted with 5 N NaOH) 
TBE (10x) 0.89 M Tris base, pH 8.3 
 0.89 M boric acid 
Running buffer for SDS-PAGE 
electrophoresis 
25 mM Tris 
 192 mM Glycine 
 0.1% (w/v) SDS 
Transfer Buffer for Western blot 
 
25 mM Tris 
192 mM glycine 
10% methanol 
RIPA buffer 
10 mM Tris-HCl pH8 
150 mM NaCl 
1 mM EDTA 
1% NP-40 
0,1% SDS 
NET buffer 1% (v/v) Triton X-100 
 50 mM Tris-HCl pH 7.4 
 5 mM EDTA 
 150 mM NaCl 
 20 mM NaF 
 1 mM Na3VO4 
4x Laemmli Sample Buffer 250 mM Tris-HCl pH 6.8 
 8% (w/v) SDS 
 40% (v/v) glycerol 
 10% b-mercaptoethanol 
 0.06% (w/v) bromophenol blue 
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TBST(10X) 
100mM Tris.HCl pH 7.6 
150mM NaCl,  
0.5% Tween® 20  
Table 2.2 List of buffers and solutions.  
2.1.5 Kits 
Listed below in Table 2.3 are the kits that were used in this work. Unless stated 
otherwise, the manufacturer’s recommendations were followed. 
Application Name Supplier 
Plasmid DNA extraction 
from E. Coli bacteria 
cultures 
NucleoBond Xtra 
Midi® , NucleoSpin 
Plasmid ® 
Macherey-Nagel, Düren, 
Germany 
Plasmid DNA extraction 
from agarose gels 
NucleoSpin Extract II 
® 
Macherey-Nagel, Düren, 
Germany 
RNA extraction  RNAeasy Plus ® Qiagen, Hilden, Germany 
Renilla luciferase 
reporter assay (or Dual 
luciferase reporter assay) 
 
Renilla-Luciferase-
Reporter assay 
system 
(or Dual luciferase-
Reporter assay 
system) 
 
Promega, Madison, WI, US 
Quantitative PCR 
(qPCR) 
 
 
Senescence associated 
β-gal activity 
 
 
SYBR Green PCR 
Master Mix 
 
 
Cellular Senescence 
Assay Kit(SA-β-gal 
Staining) 
 
 
Applied Biosystems (ABI), 
Warrington, UK 
 
 
 
Cell Biolabs, Inc. 
 
 
 
Table 2.3 List of kits. 
2.1.6 Plasmids used for the stable and inducible HeLa cell line generation 
To generate the stable and inducible HeLa cell lines the Flp-InTM-T-RexTM 
Mammalian Expression System (Invitrogen) was applied according to the 
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manufacturer’s instructions. All the required plasmids were obtained from 
Invitrogen. Three different constructs were used to generate three different stable 
and inducible HeLa cell lines: 
pcDNA5toFRT-hFPN-EGFP 
pcDNA5toFRT-hFPN-Rluc 
pcDNA5toFRT-Rluc 
The coding sequence of human ferroportin fused to the coding sequence of 
enhanced green fluorescent protein was subcloned in pcDNA5toFRT expression 
vector (Invitrogen) by using AflII and NotI restriction sites. To generate the hFPN-
Rluc construct, EGFP was cut and renilla coding sequence was subcloned in the 
same vector by using KpnI and NotI restriction sites. pcDNA5toFRT-Rluc construct 
was obtained by subcloning Rluc in pcDNA5toFRT by using HindIII and NotI. The 
correct sequences of DNA constructs employed in the experimental studies were 
verified by DNA sequencing (GATC biotech AG, Konstanz, Germany).  
The selective antibiotics: BlasticidinS, ZeocinTM and HygromycinB were purchased 
by InvivoGen and were used at concentration 5 µg/ml, 200µg/ml and 200µg/ml 
respectively. 
2.1.7 Oligonucleotides 
All primers were purchased from Sigma-Aldrich (Taufkirchen, Germany) or 
biomers.net (Ulm, Germany). PCR primers were obtained in desalted, lyophilized 
form, and were diluted in H2O. 
 2.1.7.1 Primers used for sequencing of DNA constructs 
The following primers were used for DNA constructs used for the HeLa cell line 
generation: 
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FW 5’-3’ CMV-F: CGCAAATGGGCGGTAGGCGTG 
RV 5’-3’ BHG-REV: TAGAAGGCACAGTCGAGG 
 
2.1.7.2 Primers used for quantitative PCR analysis 
All the primers used for quantitative PCR are listed in table 2.4. 
Gene (human) FW 5’-3’  RV 5’-3’  
AZU1 tgagcgagaatggctacga gtatcgtcacgctgctggt 
 
aacctgaacgacctgatgctg atcgtcacgctgctggtga 
MAP4K3 attacccccacacaaacctg aatgagccatctcgttcacc 
EVI1 aatgcgacttaaagtgattcagtg cctaaggtggggtaaactgga 
MAP3K1 caccaccactgcatgtcaa gatctacaaaggggacatattaaagg 
TSSK2 gcaaaagtcaaatctgcctactc gttttcttgcggtcgatgat 
TEX14 ccgcaccagaagtgatcttac cccttccagggtatgtcatc 
TGFBR1 aaattgctcgacgatgttcc cataataaggcagttggtaatcttca 
NRBP1 agataaattccttgaagatgtcagg tgtcacctcctcctgctgt 
TGFBR2 tccatctgtgagaagccaca gggtcatggcaaactgtctc 
BCKDK gagaagtgggtggactttgc catagggatgaaggggaacc 
CKMT1B ggtaacatgaagagagtgtttgaaag cagccacgttcttggataagt 
OXSR1 agcccatcattacctgtgaact aaccccagcccaattctatt 
TTBK1 gccaactacgtggtcaagg cctggtcagcaggtccat 
 
ggcagacgatcagaaggagt agagacaagcaccagcgttt 
 
cattctacccccagcttcac caagggcagactgggtttt 
ITPKB tgaggggaccctaccagat ccaggctggtgcttccta 
 
tgtgaccaagccacggtacat ccctcgttttggtcttcttgaa 
ACVR1 catgaatttggcttttggaga ctttggcagtgtgacgctta 
 
tggcagagttatgaggcact atgggagtgagcgagtctct 
TLR6 tgaaacagtctcttttgagtaaatgc tccatttgggaaagcagagt 
PHKA1 caacttacttgattcacctcatcc tccccagactggtctctagg 
EPHB6 ccccggactggagaagac gggtggactataatccctttatttc 
 
ccaggaacctgccagcggtggtg ggtcagggtgaaggagtgggattcgtcttctg 
IPMK cacatgtacgggaaggacaa catattatagaattccagctctcttgg 
EPHB3 tgccaaggagtcccagtg aggtggtacggctgttgg 
PIP4K2A atggaattaagtgccatgaaaac gcatcataatgagtaaggatgtcaat 
ALDH18A1 tgacctgcagggggttatta ttttcatttccacagccagtc 
BLNK tcaaccaagccaaattcctc ccccactgtttcgacctg 
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EIF2AK1 ccacttcgttcaagacaggtg gctaaactcgtcactacaagtgaaa 
PIP5KA1 ttgctcttctcatcttttccaac cccctctttaccttagctcca 
HK3 atcgtggactgcatcgtg ttggtccagttcaggagga 
BMPR1B tttcatgccttgttgataaaggt gcttgtttaactttttgtttcctctc 
EPHA4 aagaggacagggacggagag agttatccttataccggtccatttt 
RET catcaggggtagcgaggtt gggaaaggatgtgaaaacagc 
 
gctccacttcaacgtgtc gcagcttgtactggacgtt 
RBKS aggcagtggcaagaggag cagtttttggcaaacgagaag 
EPHA8 acctcagctactaccgtgcag actggagatcaggttcactgg 
ADAM9 catgacagtgcacagctagttctaa cacactgttcccacaaatgc 
MAP2K7 ccccgacagacactgtga ggctgaatgaacagcgactc 
EPHB1 ttcgtaacagatgcaaacaagaa tattccagcccctttggatt 
AP2M1 agggcatcaagagtcagca gctcattccgacgatacttga 
CLTC ccagattctgccaattcgtt tgggttgatacccaggttct 
ACTIN ttccgctgccctgaggcactct tctgctggaaggtggacagcga 
FERROPORTIN tgctgtttgcaggcgtcatt ttgcagcaactgtgtcacagtt 
CAV1 acagcccagggaaacctc ggatgggaacggtgtagaga 
MON1A ctggaggcagacaagaac ggcgcacgaatactaccttg 
JAK2 ggtgaaagtcccatattctggt aggccacagaaaacttgctc 
NEDD4 accacaacaaccggacca gtccgactccgaggacac 
   
   GENE (MOUSE) FW 5'-3' RV 5'-3' 
MECOM (EVI1) aggaagattgaaataggcgaaa ctgcacatcacctgttctcc 
BCKDK tgctcaagaatgccatgaga tgagatcctgatgatgagatcaat 
ADAM9 tgcaaggatgaccgaagg tagtcgcagagaggcaagg 
BLNK cgaagtttacacaacgcacag ggtcatgtgatccagggagt 
ITPKB ggcgggaaaccatcagtt cttccttcttgatgccttcg 
PHKA1 tccatgtggagtctgtcctg caaccagaagttggcggtat 
IPMK gcccaagagagctggaattt tttgggcaggtgttttcg 
BMP2K ccgtccctttcatttctcac ttggagaatgttccgtcgtt 
EPHB6 cagttccagcaccccaata tgacaggccgactcttagtg 
TEX14 cagtgtcctccatgaacgaag tgcaggtatatcaaggcatca 
TLR2 ctgcactggtgtctggagtc gggcacctacgagcaagat 
TLR4 ggactctgatcatggcactg ctgatccatgcattggtaggt 
MAP3K1 gcagttttaaccttactcattttgg agttccattccaaacacctga 
MAP2K7 attgggggttggactgct ggagcctggcctctccta 
PIP4K2A caacagctcaccacccttg ggcatttaattgcataaacatcaa 
36B4 gcgacctggaagtccaacta atctgctgcatctgcttgg 
TLR6 gggttttctgtcttggctca ggtaccgtcagtgctggaa 
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FPN tgtcagcctgctgtttgcagga tcttgcagcaactgtgtcaccg 
HAMP ataccaatgcagaagagaagg aacagataccacactgggaa 
IL6 gctaccaaactggatataatcagga ccaggtagctatggtactccagaa 
TNFA tgcctatgtctcagcctcttc gaggccatttgggaacttct 
TFR1 cccatgacgttgaattgaacct gtagtctccacgagcggaata 
DMT1A  gggaagaagcagccaagg gggggtctgtgctcttagaat 
IL1Β gcaactgttcctgaactcaact atcttttggggtccgtcaact 
HFE tcttggatcctccacgtttc tcatccacatagcccctagc 
2.4 Table of primers 
2.1.8 siRNAs 
All siRNAs used to validate the screening are listed in Table 2.5. SiRNAs for 
human genes were purchased from Dharmacon as pool of 4 siRNAa sequences 
per gene (Lafayette, CO, US) (list on the left side), while others (on the right side) 
and siRNAs for murine genes were purchase from Ambion (Life Technologies) as 
single sequences. Three negative controls targeting no gene were used as 
scrambles. The first two in the list were obtained from Ambion, the last one from 
Dharmacon. All siRNAs were obtained in desalted, lyophilized form, and were 
diluted in H2O. 
siRNA ID 
(human) 
Gene 
symbol 
Gene accession 
siRNA ID 
(human) 
Gene 
symbol 
siRNA sequence 
MU-006759-
00 
PANK4 NM_018216 
 
117501 SLC40A1 CCAUGUACCAUGGAUGGGUtt 
MU-009859-
01 
PRKAG3 NM_017431 
 
15673 DNM2 GGAGCUAAUCAAUACAGUUtt 
MU-008914-
00 
AZU1 NM_001700 
 
147117 AP2B1 GGAUCCCUAUGUUCGGAAAtt 
MU-004884-
01 
DCLK1 NM_004734 
 
125716 MON1A GCUCUACAUGUGUUACAGCtt 
MU-003588-
02 
MAP4K3 NM_003618 
 
134054 EPN1 CGUGCGUGAGAAAGCUAAGtt 
MU-005025-
02 
PIK3R4 NM_014602 
 
136860 NEDD4L CCCAUCUAAUCACAGACUCtt 
MU-006530-
02 
EVI1 NM_005241 
 
607 JAK2 GGUGUAUCUUUACCAUUCCtt 
MU-003930-
02 
TGFBR2 NM_003242 
 
siRNA ID 
(mouse) 
Gene 
symbol 
Gene accession 
MU-003575-
02 
MAP3K1 NM_005921 
 
 s69749 MECOM NM_021442 
MU-004932-
01 
BCKDK NM_005881 
 
 s77071 MAP3K1 NM_011945 
MU-005379-
01 
TSSK2 NM_053006 
 
 s62904 BCKDK NM_009739 
MU-004016-
01 
MAP2K7 NM_145185 
 
 s77070 MAP2K7 NM_001042557 
MU-008885-
00 
CDK5R2 NM_003936 
 
 s232234 ADAM9 NM_001270996 
MU-006748-
00 
MVD NM_002461 
 
 s69395 BLNK NM_008528 
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MU-005386-
02 
TEX14 NM_031272 
 
 s71633 PIP4K2A NM_008845 
MU-006708-
01 
CKMT1B NM_020990 
 
 s115701 ITPKB NM_001081175 
MU-003929-
02 
TGFBR1 NM_004612 
 
 s71572 PHKA1 NM_008832 
MU-004870-
02 
OXSR1 NM_005109 
 
 s88141 IPMK NM_027184 
MU-005356-
02 
NRBP1 NM_013392 
 
 s100528 BMP2K NM_080708 
MU-004680-
02 
TTBK1 NM_032538 
 
 s65587 EPHB6 NM_001146351 
MU-004671-
01 
RPS6KB2 NM_003952 
 
 s96393 TEX14 NM_001199293 
MU-019425-
02 
PDK4 NM_002612 
 
 s76898 TLR2 NM_011905 
MU-006743-
02 
ITPKB NM_002221 
 
 s75209 TLR6 NM_011604 
MU-005389-
02 
TLK2 NM_006852 
    MU-005385-
03 
TAF1L NM_153809 
    MU-004172-03 SPHK1 NM_021972 
    MU-005041-01 TAF1 NM_004606 
    MU-005326-
00 
MLKL NM_152649 
    MU-004030-
02 
PINK1 NM_032409 
    MU-015901-01 EVI5L NM_145245 
    MU-004924-
02 
ACVR1 NM_001105 
    MU-003110-02 CSK NM_004383 
    MU-005156-01 TLR6 NM_006068 
    MU-004846-
03 
TAOK1 NM_020791 
    MU-019682-01 PHKA1 NM_002637 
    MU-010230-
00 
SQSTM1 NM_003900 
    MU-003224-
03 
CDC2 NM_001786 
    MU-003166-
02 
PTK6 NM_005975 
    MU-003125-02 EPHB6 NM_004445 
    MU-006740-
02 
IPMK NM_152230 
    MU-003123-
02 
EPHB3 NM_004443 
    MU-006786-
00 
RBKS NM_022128 
    MU-004030-
02 
PINK1 NM_032409 
    MU-003176-03 SYK NM_003177 
    MU-003923-
00 
PIM1 NM_002648 
    MU-004838-
01 
RAGE NM_014226 
    MU-003120-
03 
EPHA8 NM_001006943 
    MU-005071-01 BMP2K NM_017593 
    MU-006785-01 ALDH18A1 NM_001017423 
    MU-003121-02 EPHB1 NM_004441 
    MU-006778-01 PIP4K2A NM_005028 
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MU-003560-
06 
RAC1 NM_006908 
    MU-020353-01 BLNK NM_013314 
    MU-005359-
00 
PIM2 NM_006875 
    MU-005007-
00 
EIF2AK1 NM_014413 
    MU-004780-
02 
PIP5K1A NM_003557 
    MU-006736-
00 
HK3 NM_002115 
    MU-006705-
00 
CHKB NM_005198 
    MU-004934-
01 
BMPR1B NM_001203 
    MU-003118-02 EPHA4 NM_004438 
    MU-003170-02 RET NM_020630 
    MU-005352-
02 
MYLK2 NM_033118 
    MU-003524-01 PRKCD NM_006254 
    MU-003545-10 AURKA NM_198437 
    MU-004504-
03 
ADAM9 NM_001005845 
    MU-006760-
02 
PAPSS2 NM_004670 
    MU-003758-
04 
PRKCB NM_002738 
    MU-005306-
02 
STRADB NM_018571 
    MU-003146-
02 
JAK2 NM_004972 
    MU-005449-01 CCR2 NM_000648 
    MU-005013-01 TNNI3K NM_015978 
    MU-004926-
02 
ACVR2A NM_001616 
    MU-003163-
03 
PDGFRB NM_002609 
    MU-008442-
00 
AKAP4 NM_003886 
    MU-006754-
00 
NME5 NM_003551 
    
       scramble ID name 
     
AM4611 
Silencer 
Negative 
Control 
siRNA 
     
AM4635 
Silencer 
Negative 
Control 
siRNA 
     D-001210-03-
05 
siGENOME 
non targeting 
siRNA 3 
     2.5 Table of siRNAs. Some siRNAs for human genes (on the right side) are no longer available 
with the indicated ID. However their sequences are reported. 
2.1.9 Bacterial strain 
For propagation of vectors, the heat shock competent E.coli strain, XL1 blue, (La 
Jolla, CA, USA) was used. The genotype of this strain is the following: hsdR17, 
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supE44, recA1, endA1, gyrA96, thi, relA1, lac/F´[proAB+ lacIa, 
lacZΔM15:Tn10(TetR)]. 
2.2 Cell culture methodologies 
2.2.1 Cell lines and primary cells 
The human HeLa cell line was cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, high glucose) supplemented with 10% heat-inactivated low-endotoxin 
FCS and 1% penicillin/streptomycin. Cell cultures were maintained at 37oC under 
5% CO2. 
Bone marrow derived macrophages (BMDMs) were flushed from tibia and femur 
using ice-cold HBSS and filtered through a 70 um cell strainer. Cells were seeded 
at a density of 350.000cells/cm2 in RPMI1640-Glutamax medium supplemented 
with 10% of heat-inactivated FBS, 1% penicillin/streptomycin and 10ng/ml M-
CSF1. After 4 days, non-adherent cells were removed by washing with HBSS and 
the medium was replaced daily. 
2.2.2 SiRNA screening 
The stable and inducible HeLa cell line was established by applying the Flp-InTM-T-
RexTM system according manufacturer’s instructions. The pcDNA5/FRT/TO 
plasmid contained the coding sequence of human ferroportin fused to Renilla 
luciferase or only Renilla luciferase under the control of a tetracycline-regulated, 
hybrid human cytomegalovirus (CMV)/TetO2 promoter. For the siRNA screen the 
cell-based Renilla luciferase assay was adapted to the 384-well plate format and 
high-throughput conditions. The Protein Kinase siRNA library Thermo Fisher 
siGenome (Dharmacon) targeting protein kinases and other related genes (779 
genes) was used. The library was arrayed in 384-well white plates (Greiner Bio-
One), each well containing 1.25 pmol of a pool of 4 synthetic siRNA duplexes (final 
concentration in wells, 25 nM). Viability controls included a siRNA pool directed 
against PLK1and COPB2. As a negative control, 3 scrambled siRNAs were used. 
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Reverse transfection of HeLa cells was performed by dispensing 15 μL of 
RPMI1640-Glutamax medium together with 0.05 μL of Dharmafect1 reagent 
(Dharmacon) to the siRNA-containing 384-well plates. After 30 minutes incubation 
at ambient temperature, HeLa cells (2500 per well) were added to the siRNA 
transfection mix in a 30-μL volume of Dulbecco modified Eagle medium 
supplemented with 10% heat-inactivated low-endotoxin fetal bovine serum. Forty-
eight hours after siRNA transfection, the medium was replaced with 30 μl fresh 
medium containing 0,5 μg/ml doxycycline (Sigma-Aldrich). Three hours later 
doxycycline was removed by extensive washing with PBS and fresh culture 
medium was added to cells. Two hours later cells were incubated in absence or 
presence of 1 μg/ml hepcidin (0,4 μM) for 18 hours. After incubation cells were 
lysed with 20 μl Passive Lysis Buffer 1x (Promega) and plates were frozen. All 
dispensing steps were performed with the use of MultidropCombi dispensing 
systems (Thermo Scientific). Renilla Luciferase activity was measured by adding 
Renilla luciferase assay substrate (Promega) and quantified by Centro LB 960 
luminometer (Berthold Technologies). 
2.2.3 Validation of the screening results 
2.2.3.1 Validation in HeLa cells 
To analyze viability and hyperproliferative effects induced by siRNAs, the MTT 
colorimetric assay (Sigma-Aldrich) that measures the reduction of yellow 3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial 
succinate dehydrogenase was applied.  
Validation of data from the screen was performed in a 96-well format with single or 
pooled siRNAs targeting the candidate genes (Table 2.5). 20 μl of 250 nM siRNA 
was spotted in well-plates. Dharmafect1 (0.2 μl) diluted in 60 μl of RPMI were 
added to each well and incubated 25 min at room temperature. After incubation 10 
× 103 cells in 120 μl volume of complete culture medium (without antibiotics) were 
seeded on top of the transfection mix and cultured for 48h. After this the medium 
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was replaced with 200 μl fresh medium containing 0,5 μg/ml doxycycline. Three 
hours later doxycycline was removed by extensive washing with PBS and fresh 
culture medium was added to cells. Two hours later cells were incubated in 
absence or presence of 1 μg/ml hepcidin (0,4 μM) for 18 hours. After incubation 
cells were lysed with 100 μl Passive Lysis Buffer 1x and 30 μl of lysate was used 
for Renilla luciferase assay. 
2.2.3.2 Validation in BMDMs 
Validation of putative regulators of FPN protein stability in BMDMs was performed 
by applying direct RNA interference and following FPN protein analysis by Western 
blot. RNAi was mostly performed in a 6-well plate format, using at least 5 wells per 
a single siRNA candidate testing. BMDMs were processed as previously explained 
and seeded (700 x 103 per well) onto 6 well plates. After 4 days from seeding the 
medium was replaced and 1 day after RNAi was applied by using Lipofectamine 
RNAiMAX reagent (Invitrogen) according to manufacturer’s instructions. 7,2 µl of 
10 µM siRNA and 7,2 µl lipoRNAiMax were used and the siRNA-reagent mix was 
added to cells in medium without Pen/Strep and macrophage colony stimulation 
factor. The day after the medium was replaced with a complete one. Cells were 
scraped from the culture plate 54h after the siRNA-reagent mix drop. 1/5 of the 
lysate was used for total RNA extraction, all the rest was used for total protein 
extraction. In some cases ammonium iron(III)citrate (Sigma-Aldrich) was used at 
concentration of 50 µM for 16h. 
2.2.4 Treatment of BMDMs with TLRs ligands, cytokines and inhibitors 
BMDMs were seeded onto 6 well-plates (700x103 per well) or 10-cm dish (3,5 
x106) and treated, after 5 days from seeding, with FSL1, PAM3CSK4 (InvivoGEN), 
PamOct2C-(VPG)4VPGKG (EMC, microcollection) and LPS (Escherichia coli 
serotype O111:B4 ) at a concentration of 20 ng/ml (FSL1) and 100 ng/ml for 6, 12 
and 24h. Cells were then harvested for total RNA and protein extraction. 
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BMDMs were seeded onto 12 well-plates (350 x103 per well) and incubated, after 5 
days from seeding, in presence of mouse recombinant TNFα (GIBCO), IL6 and 
IL1β (R&D Systems) at concentration of 0,5, 0,1, 0,02, 0,005 and 0,001 µg/ml for 
6, 12 and 24h. Cells were then harvested for total RNA extraction. 
BMDMs seeded onto 12 well-plates (350 x103 per well) were incubated, after 5 
days from seeding, with the following inhibitors at the indicated final 
concentrations: LY294002(50µM), Wortmannin(1µM), PP1(10uM), 
Saracatinib(10µM), Bafetinib(10µM),  SB202190(15µM), SP600125(15µM), 
UO126(10µM), PDTC(15µM), SN50(15µM). After 30 minutes of pre-incubation, 
FSL1 (100 ng/ml) was added to the medium for 6 hours. Cells were then harvested 
for total RNA extraction. 
2.3 Molecular biology methodologies 
2.3.1 Total RNA extraction and reverse transcription 
Total RNA extraction from cells was performed with Qiagen RNAeasy Plus kit 
(Qiagen), while total RNA from tissues was isolated using Trizol (Life 
Technologies) according to manufacturer’s instruction. The concentration and 
purity of the RNA was determined by Nanodrop2000 (Thermo Scientific). 1 (or 0.5) 
micrograms of total RNA was used for reverse transcription (RT). The RNA and 1 
µl of random primers (0.2µg/µl) were denatured at 70°C for 10 min, and cooled 
down on ice for 2 min. The reverse transcription reaction mixture contained a total 
volume of 25 µl consisting of RT buffer (Fermentas), 0.4 mM dNTPs, 100 units of 
RevertAid H Minus M-MuLV Reverse Transcriptase (Fermentas), 1 µl random 
primers (0.2 µg/µl) and 1 µg of denatured total RNA. The mix was incubated at 
42°C for 90 min, then at 70°C for 10 min for stopping the reaction. The cDNA 
samples were diluted for the subsequent qPCR analysis by adding 175 µl of H20 to 
cDNA obtained from cells or 475 µl of H20 to cDNA from tissues. 
2.3.2 Quantitative PCR 
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For quantitative PCR (qPCR) following the standard RNA extraction/cDNA 
synthesis protocol (see 2.3.1.) the reaction mix (20 µl) contained 10 µl SYBR 
Green PCR Master Mix, 0.5 µM of the forward and reverse primers and 5 µl of 
cDNA. The qPCR mixture was run on ABI Prism 7500 Applied Biosystems 
(Applera Deutschland) following amplification conditions: 50°C 2 min, 95°C 10 min, 
(95°C 15 s, 60°C 15 s) × 40 cycles. Intron-spanning primers were designed to 
specifically amplify the human or murine transcripts. Sequences of the primers are 
shown in Table 2.4. Threshold cycles (Ct) were defined as the fractional cycle 
number at which the fluorescence passed the fixed threshold. Ct values were 
extracted by using the 7500 software v2.0.1 (ABI) and calculations for 
normalisation and analysis were done in Excel (Microsoft Office). The mRNA/cDNA 
abundance of each gene was calculated relative to the expression of the 
housekeeping gene 36B4 encoding for an acidic ribosomal phosphoprotein P0 
(RPLP0) and data were analyzed by applying the ΔΔCt method (Livak and 
Schmittgen, 2001).  
2.3.3 Transformation of bacteria  
Ligation mixtures (10µl) were mixed with 100 μl of the transformation-competent 
E.coli strain, XL1 blue, incubated on ice for 20 min. The cells were heat-shocked 
for 90 s at 42°C and then placed on ice for 2 min. 400 μl of LB medium was added 
and the mixture was incubated for 1h at 37°C with 1100 rpm shaking. The 
transformed bacteria were then spread on LB agar plates containing the 
appropriate antibiotic and incubated overnight at 37°C. 
2.3.4 Bacterial culture and isolation of plasmid DNA 
Single bacterial clones were incubated in 4 ml or 100 ml LB medium containing the 
appropriate antibiotic in the shaker, overnight at 37°C. To isolate plasmid DNA, the 
NucleoSpin Plasmid ®NucleoBond or NucleoBond Xtra Midi® kits were used 
according to the manufacturer’s instructions. DNA concentration was determined 
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using Nanodrop2000 (Thermo Scientific). Sequencing of DNA constructs was 
performed to confirm the sequences by GATC Biotech AG (Konstanz, Germany).  
2.3.5 DNA agarose gels 
DNA samples mixed with DNA loading buffer were loaded on 1% agarose (w/v) 
gels containing ethidium bromide. 250 ng of 1 kb or 100 bp DNA ladder used as a 
size marker allowed the estimation of the size of DNA fragments. Agarose gels 
were usually run at 100V, and visualised using a UV transilluminator (Herolab 
UVT-28 ME). 
2.3.6 Western blot analysis 
Cells were harvested by centrifugation at 13000 rpm for 30 second in cold PBS 
and cell pellets were lysed in ice-cold NET or RIPA buffer supplemented with 1X 
Complete Mini Protease Inhibitor Mixture (Roche Applied Science) and, in some 
cases, phosSTOP phosphatase inhibitors cocktail (Roche Applied Science). After 
incubation on ice for 30 min, lysates were clarified by centrifugation at 10,000 rpm 
for 10 min in a cooled microcentrifuge and supernatants were collected.  Protein 
concentration was measured using the DC Protein Assay (Biorad). Samples were 
mixed with 4X Laemmli buffer and denatured by heating at 95 °C for 5 min. For 
FPN protein analysis samples were not denatured. The samples were subjected to 
10% or 12% SDS-PAGE and the proteins were transferred to a PVDF membrane 
using wet transfer method. The membrane was blocked with 5% nonfat dry milk in 
TBS containing 0,1% Tween 20 (TBS/T) for 1 h at room temperature. Primary 
antibodies indicated in 2.1.3 were incubated for 1h at room temperature or over-
night. The membranes were then washed with TBS/T and incubated with anti-
rabbit IgG secondary antibody (Sigma-Aldrich). After washing, the immune 
complexes formed on the blot were visualized by ECL-Plus (Amersham 
Biosciences), quantified with Vilber Lourmat (Eberhardzell, Germany) Fusion-FX 
Chemiluminescence system and normalized to β-actin.   
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2.3.7 Plasma biochemistry and tissue iron quantification 
Plasma iron concentration and unsaturated iron binding capacity were assessed 
using the SFBC and UIBC kits (Biolabo, Maizy, France). Transferrin saturation was 
calculated using the formula SFBC/(SFBC+UIBC)X100. Tissue non-heme iron 
content was measured using the bathophenanthroline method and calculated 
against dry weight tissue (Torrance and Bothwell, 1968). 
2.3.8 Splenic macrophage isolation 
Mouse macrophages were magnetically separated from splenic cell suspensions 
by CD11b MicroBeads (MACS) according to manufacturer’s instruction. 
2.3.9 DAB-enhanced Perls’ staining 
Tissues were fixed in 10% formalin overnight at room temperature and embedded 
in paraffin. Microtome sections, 5-μm thick, were stained with potassium 
ferrocyanidesolution (Sigma-Aldrich) followed by 3,3-
diaminobenzidinetetrahydrochloride (DAB) (Sigma-Aldrich) development. 
2.4 Mice 
C57BL/6N wild type male mice aged between 10 and 11 weeks were purchased 
from Charles River Laboratories.  C326S-FPN mutant mice on a C57BL/6 
background were generated as reported (190). Mice were housed in the EMBL 
animal facility under constant light-dark cycle and maintained on a standard diet 
containing 220 ppm iron (Teklad 2018S, Harlan, Rossdorf, Germany) with ad 
libitum access to water and food. Inflammation was induced by intra-peritoneal 
injection of FSL1 (InvivoGEN) and LPS (Escherichia coli serotype O111:B4) 25 
ng/g bodyweight, unless otherwise indicated. Control mice were injected with an 
equivalent volume of sterile saline solution. Heparinized blood was collected by 
cardiac puncture from mice euthanized by CO2 inhalation. All mouse breeding and 
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animal experiments were approved by and conducted with the guidelines of the 
EMBL institutional Animal Care and Use Committee. 
2.5 Statistical analysis 
For analysis of the screening data, the CellHTS2 package (Bioconductor) was 
used to calculate z-scores as a measure of the generated phenotype. To obtain z-
scores this median was subtracted from each logarithmic value and divided by the 
median absolute deviation of a whole plate. High z-scores were indicative of 
reduced FPN activity, low z-scores were indicative of increased FPN activity. The 
threshold value was computed as the mean signal of the distribution plus two times 
the standard deviation. Mean z-scores for control siRNAs were first calculated 
within each replicate and then between replicates. For the screening data the 
mean z-score of 2 replicates was calculated.  
All the other results from this study are expressed as a mean. At least 3 
independent experiments were represented as mean plus or minus standard 
deviation (SD) or standard error (SEM). Two tailed, Student’s t test was used for 
estimation of statistical significance. 
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3 RESULTS 
3.1 Establishment of a fluorescent cell-based assay to assess hepcidin-mediated 
ferroportin regulation 
The first screening strategy I optimized was based on cell-image analysis. The labs of 
Jan Ellenberg and Rainer Pepperkok (EMBL) developed a robust protocol for the 
reverse transfection of cells on small interfering (si)RNA arrays, which, in combination 
with multi-channel immunofluorescence or time-lapse microscopy, was suitable for 
genome-wide RNA interference (RNAi) screens in intact human cells (137, 138). This 
innovative assay was already used for the successful identification of regulatory genes 
(139). 
To establish a fluorescent read-out of FPN expression I generated a stable HeLa cell 
line that expressed a human FPN/EGFP fusion protein in an inducible manner and 
adapted this cell-based assay to the high throughput setting of RNAi arrays and 
automated fluorescence microscopy. In this cellular model hepcidin treatment was 
expected to shift the fluorescence from the outer membrane to intracellular vesicles. By 
measuring intensity and localization of the fluorescent signal both before and after 
hepcidin application, the consequences of specific gene interference could be 
assessed. For instance, if fluorescence was exclusively detected on the cell surface 
before and after hepcidin addition, the respective siRNAs inhibited hepcidin-mediated 
FPN-EGFP internalization, as expected for kinases, which were supposed to be 
responsible for the hepcidin-mediated FPN phosphorylation. This approach provided in 
principle several advantages. It allowed visualizing FPN internalization steps and 
monitoring potential siRNA lethal effects. However it required a robust control 
phenotype in order to quantify fluorescent read-out changes. 
HeLa cells were shown to support hepcidin-mediated FPN internalization (28) and, 
importantly, were used to set up a robust protocol of reverse transfection of cells on 
siRNA arrays (137, 139), making the usage of this cell line ideal for my purpose. To 
establish a stable HeLa cell line I applied the FlipIn T-Rex system (Invitrogen) that 
allowed me to generate a cell line stably expressing the Tet Repressor gene under the 
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control of the constitutive human cytomegalovirus promoter and the FPN-EGFP fusion 
gene under the control of the inducible cytomegalovirus promoter with Tet Repressor 
binding site, inserted in a single flipase (Flp) Recombination Target (FRT) site. The 
system provided in principle an isogenic stable cell line, with the same genetic 
background and the same inducibility level (Figure 3.1).  
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Figure 3.1 Stable and inducible hFPN-EGFP HeLa cell line generation. The pFRT/lacZeo plasmid 
introduces a single FRT site into the genome and stably expresses the lacZ-Zeocin fusion gene under the 
control of the SV40 early promoter. FRT sites serve as binding and cleavage site for the Flp recombinase 
in the following step. Zeocin-resistant clones can be screened to identify those containing a single 
integrated FRT site. Once host cell with an integrated FRT site has been created, the insertion of hFPN-
EGFP is rapidly achieved by the co-transfection with two further vectors. One vector constitutively 
expresses the Flp recombinase enzyme and the other (pcDNA5FRT) contains the hFPN-EGFP under the 
control of an inducible promoter with Tet repressor binding domains. Thus, in presence of 
the Tetracycline repressor the transcription is inhibited, but after adding tetracycline or doxycycline the 
repressor is blocked and the transcription is achieved. The pcDNA5FRT vector also contains the 
hygromycin resistance gene with a FRT site embedded in the 5′ coding region. The hygromycin 
+FLP   + pcDNA5/TO/FRT/hFPN-EGFP 
FPN-EGFP 
FPN-EGFP 
FLP-mediated recombination 
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resistance gene lacks a promoter and the ATG initiation codon. Proper integration of pcDNA5/FRT 
plasmid places the ATG initiation codon (from pFRT/lacZeo) in frame with the hygromycin resistance 
gene, and inactivates the lacZ-Zeocin fusion gene. Thus, stable Flp-In expression cell lines can be finally 
selected for hygromycin and blasticidin resistance and Zeocin sensitivity. 
Stable FlipIn T-Rex clones were selected for antibiotic resistance according to the 
protocol and tested for inducibility and the hepcidin response by Western blotting and by 
epifluorescence microscopy. Two problems arose over time: instability of the construct 
integration and lack of isogenicity among the cell population. To overcome these 
problems I generated a second, independent inducible stable cell line using a different 
type of HeLa cell and applying the same protocol (Figure 3.1). In this second attempt I 
tried to single out an isogenic population by additionally picking single clones even after 
the FPN-EGFP integration, when the cell population was already supposed to be 
isogenic according to the principle of the system.  All clones were screened for β-
galactosidase activity (that must be lost after FPN-EGFP integration) and for FPN-
EGFP expression after induction with wide field microscopy. The most responsive 
clones to hepcidin addition were selected. Nevertheless neither of the two cell lines 
guaranteed the feasibility of the screening. Cell image-based screening required a cell-
based assay with a robust read-out under control conditions: 1) Fluorescence signal 
indicative of FPN expression should be localized on the cell surface after induction by 
doxycycline and 2) should be undetectable after hepcidin treatment. Unfortunately the 
phenotype obtained with the stable lines did not seem to satisfy these requirements. In 
the first stable line (HeLa FPN-EGFP-clone C8) only few positive cells expressed the 
EGFP signal on the plasma membrane which was weak and required a long induction 
time. On the other hand, the second stable line (HeLa FPN-EGFP-clone C10) showed a 
very strong fluorescence signal even after a very short induction with a low doxycycline 
concentration, but the cells clustered together precluding single cell analysis. Although 
in both cases hepcidin treatment caused a fluorescence shift from the outer membrane 
to intracellular vesicles, these vesicles were preserved for long time after incubation 
with hepcidin (Figure 3.2). The intracellular fluorescence persistence of the vesicles 
prevented to establish a robust reference control and to perform the quantification of the 
fluorescent signal. 
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Figure 3.2 Hepcidin effect on HeLa stably expressing human FPN-EGFP fusion protein. Stable 
HeLa cells originated from two different clones were treated with doxycycline (2 ng/µl for 12 hours for the 
clone C8 and 0.05 ng/µl for 2.5 hours for clone C10) to induce FPN expression. After induction cells were 
washed out to remove doxycycline and cultured in fresh medium for additional 12 hours. They were then 
incubated for 4 hours in absence or presence of 0,4 µM purified human hepcidin. Images were acquired 
by fluorescence microscopy (Zeiss CellObserver). 
 
3.2 Establishment of hFPN-Rluc reporter assay as alternative siRNA screening system 
To circumvent the problems described in paragraph 3.1, I generated a new stable and 
inducible HeLa cell line expressing the hFPN coding sequence fused to a renilla (Rluc) 
reporter gene by using the pcDNA5/TO/FRT hFPN-Rluc vector (Figure 3.3) and 
HeLa FPN-EGFP-clone C8 
HeLa FPN-EGFP-clone C10 
- hepcidin 
Possible 
degradation/synthesis 
vesicles ? 
+hepcidin 
-hepcidin +hepcidin 
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applying the protocol previously described (Figure 3.1). In this system Rluc activity was 
indicative of FPN expression levels and provided a sensitive and fast read-out of its 
down regulation following hepcidin treatment. Although this approach did not permit 
monitoring intermediate stages of FPN internalization and lethal siRNA effects, it was 
technically less complex. 
 
Figure 3.3 pcDNA5-hFPN-Rluc vector map. 
3.2.1 Optimization of the screening protocol 
Using the HeLa FPN-Rluc cell line, I optimized the screening strategy. One of the most 
relevant advantages of the stable and inducible cell line system was the presence of the 
inducible promoter which allowed to “switch on and off” the FPN reporter gene 
expression by adding and removing doxycycline from the medium. This modulation was 
an important advantage to prevent the override of the hepcidin response. If FPN-Rluc 
would be continuously expressed, it would be hard to quantify its reduction, mediated by 
hepcidin, thus preventing a solid analysis of hepcidin effects. However I observed that 
doxycycline removal from the medium didn’t immediately stop FPN-Rluc expression 
which continued to increase at some extent after the inducer was washed out. To 
optimize the hepcidin-mediated FPN response under my experimental conditions I 
tested several parameters: time of cells cultured in fresh medium after doxycycline 
washout, hepcidin concentration and hepcidin incubation time. The incubation time with 
hepcidin appeared to be the most relevant one. As shown in figure 3.4A the longer 
hepcidin treatment was prolonged, the greater the reduction in FPN-Rluc activity. 
Similar results were also obtained with 20xfold lower hepcidin concentration (Figure 
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3.4B) suggesting that in this experimental system FPN degradation was a slow process 
which required low amount of hepcidin.  
 
Figure 3.4 FPN degradation is a slow process, which is induced by low hepcidin amounts. (A) 
FPN-Rluc expressing HeLa cells were induced with doxycycline (0,5 ng/µl) for 3h. After induction 
doxycycline cells were washed and incubated in fresh medium. After 2h they were incubated in the 
presence or absence of hepcidin (1 µg/ml) for the indicated times. Rluc activity was measured after cell 
lysis. (B) Cells were induced as in A and then treated with hepcidin at increasing concentration for 18h. 
All data are reported as means ± SEM, *P<0,05, **P<0,01, Student’s t test. 
 
Controversial data were published about the hepcidin-mediated FPN internalization, 
making difficult the identification of positive siRNA controls to add in the screening. 
However during the optimization phase of the assay I tested some siRNAs targeting 
mediators of clathrin-dependent endocytosis which was the first proposed mechanism 
initiating the FPN internalization (97). In particular, members of clathrin adaptor 
complex, such as AP2M and AP2B as well as dynamin (the GTPase responsible for 
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endocytosis) were examined. In my pilot screening shown in figure 3.5 I also included 
FPN siRNA, as knockdown efficiency indicator and some siRNAs known to induce cell 
death, such as polo-like kinase 1 (PLK1), ubiquitin C (UBC) and Coatomer Protein 
Complex (COPB) routinely used in the lab of Prof. Boutros as viability controls in 
kinome and genome-wide screening. In addition, caveolin was tested as component of 
lipid rafts (the other pathway proposed to mediate FPN endocytosis in 
macrophages)(101) while MON1a was included as modulator of the FPN trafficking to 
the surface of iron-recycling macrophages, according to one publication (140). Finally, I 
also examined the effect of the siRNA targeting NEDD4, the E3 ubiquitin ligase reported 
to be responsible for the hepcidin-independent FPN internalization induced by low 
intracellular iron level (141). I expected the RNA interference of some of these 
transcripts to alter the extent of FPN-Rluc reduction upon hepcidin addition. 
 
 
Figure 3.5 Pilot screen. FPN-Rluc HeLa cells were seeded on siRNAs targeting the indicated human 
transcripts. After 48h cells were induced by doxycycline addition and processed as described in figure 3.3 
by using 1 µg/ml hepcidin for 18h. UBC: ubiquitin C, COPB: coatamer protein complex, PLK1: polo like 
kinase1, FPN: ferroportin1, CAV: caveolin, CLTC: clathrin, AP2B, AP2M: adaptor protein beta2, mu2, 
DNM1: dynamin1, MON1a: mon1 secretory trafficking family member A, NEDD4: Neural Precursor Cell 
Expressed, Developmentally Down-Regulated 4 
 
Unfortunately, despite the good knockdown efficiency (data not shown) achieved with 
most of the genes tested by measuring their mRNA level reduction, the depletion of the 
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indicated transcripts only mildly affected the hepcidin-mediated reduction of Rluc activity 
compared to the one observed with scramble control. Nevertheless I selected AP2M 
and NEDD4 siRNAs as controls for the screening in addition to siRNAs affecting viability 
(PLK1 and COPB) and FPN siRNA controls which, on the other hand, consistently 
reduced Rluc activity levels as expected. 
 
3.3 RNAi screen for kinases and related signaling proteins 
In collaboration with Prof. Boutros lab I performed a focused RNAi screen targeting a 
limited number of genes (779), predominantly encoding kinases and related proteins 
that, at this stage of the project, were expected to control FPN internalization and 
degradation. The Protein Kinase siRNA library Thermo Fisher siGenome contained pool 
of 4 different siRNA sequences per gene. The usage of siRNA pools rather than single 
sequence in principle ensured a greater phenotypic penetrance, however it also raised 
the risk of possible off-target effects. The cell-based Renilla luciferase assay was 
adapted to the 384-well plate format and high-throughput conditions and three 
scrambled-negative silencer-siRNAs were spotted as negative controls per each plate. 
The stable integration of one copy of FPN-Rluc gene in the genome of the cells 
overcame in this case the need of controlling the transfection efficiency which was 
usually required in case of transient transfection of similar reporters. On the other hand 
it also resulted in much lower gene-reporter expression levels demanding more 
sensitive detection system. According to the scheme in figure 3.6 HeLa-FPN-Rluc cells 
were reversed transfected with siRNAs spotted in 384-well plates. Forty-eight hours 
later, FPN expression was induced by doxycycline. Three hours later doxycycline was 
removed by extensive washes to stop FPN induction and fresh culture medium was 
added to the cells. They were then incubated in the presence or absence of hepcidin for 
additional 18 hours. Cells were finally lysed and plates were frozen. Rluc activity was 
measured the day after by adding Renilla luciferase assay substrate and quantified by 
luminometer. 
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Figure 3.6 Screening  strategy. 
 
The screening was performed in duplicate, each replicate with and without hepcidin 
treatment. Computational data analysis using the Bioconductor package cellHTS2 
assessed the quality of the assay (142) (Figure 3.7). On the level of individual plates the 
scatterplot between replicates (Figure3.7A) assessed the reproducibility of the assay 
and the Sperman rank correlation (0.78) quantified the spread of the data. Data were 
normalized to the plate median. The Z-score represented a measure of the generated 
phenotype scored for its statistical significance: large positive z-scores were indicative 
of reduced FPN-Rluc activity, negative z-scores were indicative of increased FPN-Rluc 
levels. These values were calculated taking into account the mean and the standard 
deviation of the whole distribution according to this formula: Zkj=± ykj - M/S where ykj was 
the normalized value for the kth well in the jth replicate, M was the mean and S the 
_______________________________________________________________Results 
62 
standard deviation of the y values. The final z-score was calculated as the mean z-
scores between replicates. As expected, z-scores of negative control siRNAs 
(scrambles) distributed around 0 while FPN RNAi and viability controls resulted in high 
positive z-scores. The threshold value was computed as the mean of the distribution 
plus two times the standard deviation (Figure 3.7B). NEDD4 and AP2M1 siRNAs did not 
show significant effects on FPN regulation (Figure 3.7C) confirming the mild phenotype 
already observed in the pilot screening. 
 
Figure 3.7 Evaluation of the screening quality. (A) Z-score correlation between the two replicates. 
Spearman rank correlation is 0.78. (B) Z-score distribution of the screening. The red bars represent the 
threshold values for potential FPN repressors (negative z-score) and potential FPN activators/stabilizers 
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(positive z-score). Scramble, FPN and viability controls are indicated. (C) Box plot distribution of the data. 
Scrambles, FPN, PLK1, COPB, NEDD4 and AP2M1 are indicated. 
The analysis of the screening performed in the absence of hepcidin treatment allowed 
for the identification of putative FPN activators/stabilizers, whose depletion down 
regulated FPN-Rluc signal and putative FPN repressors, whose depletion increased 
FPN-Rluc activity (Figure 3.8). However some siRNAs, causing Rluc activity decrease, 
were expected to affect cell viability giving false positive read-out of FPN regulation. 
Previous cell viability screening performed in HeLa cells in Prof. Boutros lab had already 
identified some of them. These and other genes known to be key component of cell 
cycle (listed in red) were excluded from the hit list in the validation phase. Interestingly, 
JAK2 kinase reported to be a key component of FPN internalization mechanism (97) did 
not cross the threshold (z.score: -1.34), further questioning its role in this molecular 
process. 
Candidate FPN activators/stabilizers          Candidate FPN repressors 
gene z-score 
 
gene z-score 
PANK4 3,89 
 
PDK4 -2,63 
FGFR3 3,81 
 
ITPKB -2,55 
PRKAG3 3,43 
 
TLK2 -2,48 
CDC2L2 3,38 
 
TAF1L -2,37 
AZU1 3,24 
 
SPHK1 -2,36 
DCAMKL1 2,97 
 
TAF1 -2,34 
MAP4K3 2,89 
 
FLJ34389 -2,29 
DCK 2,76 
 
PINK1 -2,19 
PIK3R4 2,75 
 
LOC115704 -2,18 
EVI1 2,68 
 
ACVR1 -2,18 
NEK11 2,62 
 
CSK -2,17 
TGFBR2 2,55 
 
TLR6 -2,16 
MAP3K1 2,53 
 
KIAA1361 -2,13 
BCKDK 2,5 
 
PHKA1 -2,1 
STK22B 2,5 
 
SQSTM1 -2,08 
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ERN1 2,46 
 
CDC2 -2,08 
MAP2K7 2,34 
 
RAGE -2,04 
CDK5R2 2,29 
 
PTK6 -2,01 
MVD 2,29 
 
EPHB6 -1,99 
CDC2L1 2,19 
 
IMPK -1,97 
TEX14 2,18 
 
MGC26597 -1,96 
CHEK1 2,17 
   
CKMT1 2,17 
   
TGFBR1 2,09 
   
OSR1 2,07 
   
NRBP 2,06 
   
PMVK 2,06 
   
EXOSC10 2,03 
   
PIK3C2A 2,03 
   
WEE1 2,01 
   
CNKSR1 2 
   
TTBK1 1,82 
   
RPS6KB2 1,7 
   
 
Figure 3.8 Hit list of hepcidin-independent FPN regulators. Genes in red were not included in the 
validation process. 
 
The hepcidin treatment applied to the cells in the screening aimed at identifying 
potential modulators of the hepcidin-mediated FPN internalization and degradation. For 
this purpose z-scores were separately calculated for each siRNA (as previously 
described) in absence and in presence of hepcidin and the correlation between them 
was analysed (Figure 3.9). The lack of correlation identified genes that altered the 
hepcidin-mediated FPN-Rluc reduction, increasing or reducing the ratio between Rluc 
activity measured in absence and in presence of hepcidin.  
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Figure 3.9 Z-score correlation between samples incubated in absence or presence of hepcidin. Z-
scores were calculated for each siRNA and normalized to the median of each plate in absence and in 
presence of hepcidin treatment, separately. The correlation between all samples was plot. 
 
Although for most genes FPN-Rluc regulation showed correlation, some genes were 
identified as possible hepcidin-dependent FPN regulators. The final z-score assigned to 
these candidates represented the difference between the z-scores calculated in 
presence and in absence of hepcidin treatment. Low z-scores were indicative of siRNAs 
increasing the hepcidin-dependent Fpn-Rluc reduction, high z-scores were indicative of 
siRNAs impairing this process. High negative z-scores were assigned to many 
candidates, while only few high positive z-scores were identified. To focus on a 
reasonable number of candidates for both categories for validation experiments, the 
threshold of the resulting distribution was set asymmetrically (3xfold the standard 
deviation for negative z-scores and 1.2x fold the standard deviation for positive z-
scores) (Figure 3.10). Therefore, I chose 21 siRNAs which potentially functioned as fine 
modulators (“repressors”) of the FPN degradation process, which was exacerbated after 
their depletion. In addition I selected 8 candidates potentially required for the FPN 
internalization and degradation pathway (activators), as the RNA interference of their 
transcripts slowed down or prevented the FPN-Rluc decrease after hepcidin addition 
(Figure 3.11). 
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Figure 3.10 Distribution of z-score ratios between sample plus and minus hepcidin. The red bars 
represent the threshold values. 
 
Candidate “repressors”                                    Candidate activators 
gene diff score  gene diff score 
EPHB3 -15,10  MYLK2 3,06 
RBKS -7,27  PRKCD 3,18 
PINK1 -5,08  PANK4 3,73 
SYK -4,83  STK6 5,25 
PIM1 -4,17  ADAM9 1,20 
RAGE -4,09  PAPSS2 1,20 
EPHA8 -4,07  PRKCB1 1,21 
BMP2K -4,03  ALS2CR2 1,40 
ALDH18A1 -4,00    
EPHB1 -3,98    
PIP4K2A -3,90    
RAC1 -3,88    
BLNK -3,84    
PIM2 -3,84    
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EIF2AK1 -3,73    
PIP5K1A -3,54    
HK3 -3,52    
CHKB -3,48    
BMPR1B -3,37    
EPHA4 -3,16    
RET -3,10    
 
Figure 3.11 List of putative regulators of hepcidin-dependent FPN internalization and degradation. 
 
3.4 Validation of the screening results 
Within the 779 screened genes, the high throughput assay identified 21 FPN-Rluc 
putative activators, 21 putative repressors, 21 putative “repressors” of hepcidin-
mediated FPN internalization and degradation and 8 potential activators. One of the 
limitations of the assay system was the impossibility to monitor cell morphology and 
viability throughout the screening process. This issue was of particular importance for 
the group of candidates which caused a reduction in the FPN-Rluc signal. To identify 
siRNAs inducing viability or hyperproliferation effects I applied a MTT colorimetric assay 
that measured the reduction of 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) by mitochondrial succinate dehydrogenase. The reduction of MTT only 
occurs in metabolically active cells, thus the level of the enzyme activity represented a 
measure of the cell viability and activity. PLK1 siRNA was used as positive control for 
toxicity. NNM5, ACVR2A and AKAP4 were not identified as hits in the screening, 
resulting in z-scores analogous to scramble, however they were included in the initial 
phase of validation as additional negative controls. The MTT assay did not show 
hyperproliferation effects in consequence of any gene knockdown, nevertheless in 
several cases the metabolic activity of the cells was reduced (red bars) suggesting 
toxicity (Figure 3.12). These candidates were excluded from the following validation 
approaches. 
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Figure 3.12 MTT assay identifies cytotoxic effects.  The mitochondrial succinate dehydrogenase 
activity was measured after knocking down all the indicated genes. 70% of residual enzymatic activity 
identified toxicity and correlated with cytotoxic effects assessed through visual inspections of cells. Red 
bars indicate the siRNAs which induced cytotoxic effects. Data are means from 2 independent 
experiments ± SD. 
 
The screening was performed in duplicates by using a pool of 4 siRNA sequences per 
target gene. To validate the generated hit lists I first tested the corresponding RNAi in 
several additional independent experiments in the same experimental conditions as 
performed for the screening. For 14 potential activators/stabilizers and 5 potential 
repressors of FPN, I confirmed the FPN-Rluc decrease and increase, respectively 
(Figure 3.13 A, B). To further enhance confidence in these results, I transfected either 
the siRNA pool directed against the respective candidates or each single siRNA 
contained within the siRNA pool, separately (Figure 3.13 C, D). For most of the genes 
the Rluc regulation I observed with the pool was confirmed with more than one single 
siRNA sequence.  
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Figure 3.13 Validation of FPN putative regulators by applying pool of 4 siRNA sequences (A, B) or 
single siRNA sequences (C, D) per gene.  Rluc activity was measured following the knock down of the 
indicated genes. All data are reported as means ± SD from 5 independent experiments (A, B) and from 2 
independent experiments (C, D) *P<0,05, **P<0,01, ***P<0,001, ****P<0,0001, Student’s t test. 
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High throughput RNA extraction methods did not provide sufficient amounts of RNA to 
evaluate the knockdown efficiency achieved by all siRNAs by measuring their mRNA 
level reduction. Because of this technical limitation I decided not to correlate the FPN 
phenotype with the knockdown efficiency of each siRNA sequence. I therefore chose to 
assess the specificity of the candidate gene knockdown by applying an alternative 
strategy.  
The flippase recombination target site used, integrates the FPN-Rluc construct into a 
specific locus which can be also targeted by another gene as control (Figure 3.1). 
According to this principle, I generated a stable and inducible HeLa cell line which 
expressed only the Rluc reporter and I tested Rluc regulation in parallel to FPN-Rluc 
upon the RNA interference of the candidates by applying the same screening strategy in 
the two cell lines. The pool of 4 siRNA sequences was used for the RNAi of each 
candidate. siRNAs inducing significant Rluc regulation in the HeLa-Rluc cell line 
identified unspecific hits (Figure 3.14). According to this, 8 candidates out of 14 were 
confirmed and included in the final hit list of FPN activators. 
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Figure 3.14 Validation of FPN putative regulators by comparing siRNA effects in HeLa-FPN-Rluc 
and HeLa-Rluc cell lines. Rluc activity was measured upon the candidate knockdown in HeLa cells 
expressing FPN fused with Rluc (A, B) and in HeLa cells expressing only Rluc (C, D). Putative FPN 
activators are indicated in (A) and (C). Putative FPN repressors are indicated in (B) and (D). Light violet 
bars represent unspecific regulators of FPN. Data are means ± SD from 5 independent experiments, 
*P<0,05, **P<0,01, ***P<0,001, ****P<0,0001, Student’s t test. 
 
The validation of the putative hepcidin-dependent FPN regulators was also performed. 
For these hits I measured Rluc activity of cells subjected to RNA interference and 
simultaneously treated with or without hepcidin. The ratio between the resulting values 
(without and with hepcidin treatment) was calculated and plotted. Because of a high 
variability of the assay five repetitions of the experiments were performed. From the 16 
putative hepcidin-dependent FPN-Rluc regulators tested, 4 showed a consistent 
hepcidin-dependent phenotype (Figure 3.15 A). Noteworthy by analyzing the Rluc 
activity only in absence of hepcidin treatment I observed that for 10 candidates FPN-
Rluc expression was significantly modulated irrespectively of hepcidin treatment 
indicating that the lack of these genes affected FPN-Rluc protein level rather than its 
hepcidin-mediated regulation (Figure 3.15 B). These candidates were then subjected to 
the same validation strategy applied to hepcidin-independent hits, by testing the effects 
of their corresponding siRNAs in HeLa cells expressing only the reporter protein. 
Seventy percent of them showed specific FPN regulation (Figure 3.15 C).  
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Figure 3.15 Validation of hepcidin-dependent FPN putative regulators. (A) For each experiment RNA 
interference of candidates was performed in duplicate. Samples were then incubated in presence or 
absence of hepcidin and subjected to the screening strategy described in Figure 3.5. Rluc was measured 
in both conditions and the ratio was calculated.  (B, C) Rluc expression in absence of hepcidin treatment 
was measured in HeLa cells expressing FPN-Rluc (B) and in HeLa cells expressing only Rluc (C). Data 
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are means ± SD from at least 3 independent experiments, *P<0,05, **P<0,01, ***P<0,001, ****P<0,0001, 
Student’s t test. 
The validation strategy I applied yielded the following final lists of candidates: 
FPN activators or stabilizers (siRNAs reducing FPN-Rluc signal)  : 
AZU1                         
EVI1                                 
MAP3K1                   
TEX14                        
BCKDK                     
MAP2K7                 
CKMT1B                
TTBK1                  
EIF2AK1           
RBKS            
ADAM9    
 FPN repressors (siRNAs increasing FPN-Rluc signal) : 
ITPKB               
TLR6                  
PHKA1                     
EPHB6                  
IPMK                  
EPHB3            
EPHA8                
BLNK 
BMP2K 
 Regulators of the hepcidin-mediated FPN internalization/degradation (siRNAs accelerating hepcidin-induced FPN-
Rluc reduction) : 
ALDH18A1              
PIP4K2A 
BLNK 
EIF2AK1 
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By inquiring the biological database and web resource STRING (Search Tool for the 
Retrieval of Interacting Genes/Proteins) I determined functional links between some 
candidates. For instance, association in curated database linked MAP2K7 to MAP3K1 
and IPMK to ITPKB (Figure 3.16). Enrichment analysis of biological processes was 
limited by the use of the sole kinase library as reference dataset. However arbitrary 
extension with predicted functional partners derived from high-throughput experimental 
data, from the mining of databases and literature, and from associations based on 
genomic context (143), allowed identifying of some shared pathways. In particular, 
TLR6, ITPKB, MAP3K1, AZU1, MAP2K7, BLNK, EVI1 and ADAM9 turned out all 
associated with immune system processes.  
 
Figure 3.16 Identification of functional links between candidates by STRING analysis. 
Engineered cell lines represented a powerful tool to study FPN regulation in a high 
throughput setting but they yet remained an artificial system. The physiological role of 
the candidate regulators needed to be investigated in cell types which expressed FPN 
at endogenous levels and which are more relevant for iron metabolism. Human 
macrophage cell lines met these requirements, however the lack of a working antibody 
against human FPN protein considerably restrained experiment feasibility.  As a well-
established ex vivo system expressing high FPN protein levels, murine bone marrow 
derived macrophages (BMDMs) emerged as a valid alternative. Furthermore the key 
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role that macrophages play in immune response made this cell type ideal to learn about 
the protein candidates related to immunological functions.  
The whole candidate selection strategy I applied is summarized in figure 3.17.  
 
 
Figure 3.17 Selection process of FPN candidate regulators. 
 
Most validated regulators of FPN expression conferred hepcidin-independent FPN 
protein regulation. For the validation in BMDMs I focused on 14 mouse homologs 
(MECOM, MAP3K1, BCKDK, MAP2K7, ADAM9, BLNK, ITPKB, PHKA1, BMP2K, 
TEX14, TLR6, PIP4K2A, IPMK, EPHB6), the majority associated with immune 
processes. I applied single siRNA sequence per gene and I then examined the FPN 
protein level by western blotting analysis. Unfortunately the quality of polyclonal 
antibodies against mouse FPN substantially dropped over this validation phase. 
Different batches showed variable quality, compromising the analysis between 
experiments, thus making quantitative analysis difficult. Nevertheless I could observe 
FPN protein increase following 6 transcript depletions (Figure 3.18 A) in iron-replete 
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BMDMs, despite a quite variable, and sometimes low, knockdown efficiency (Figure 
3.18 B). The stimulation of the cells with ferric ammonium citrate (FAC) aimed at 
increasing the FPN expression and the antibody detection level and at overcoming the 
hepcidin induction observed upon some transcript interferences (Figure 3.18 C). Unlike 
HeLa cells, BMDMs were reported to express hepcidin, especially after inflammatory 
stimulation (61). Hepcidin mediates FPN protein degradation, thus the detected rise in 
hepcidin level could override the gene specific RNAi effects on FPN protein stability, 
invalidating any resulting observation. However in cells treated with iron I did not 
observe modified hepcidin expression profiles and I could validate the siRNA-mediated 
FPN protein alterations.  
 
 
Figure 3.18 Validation of putative FPN regulators in BMDMs. (A) Representative western blot analysis 
and quantification of FPN protein level upon knocking down the indicated transcripts. β-actin was used as 
loading control. (B) The knock down efficiency of the indicated siRNAs was measured by RT-qPCR by 
analyzing the reduction of the relative target transcript calibrated to 36B4 mRNA level. Results are 
presented as a fold change ± SD compared to samples transfected with scrambled siRNA from at least 3 
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independent experiments. (C) Hepcidin mRNA relative expression was measured in BMDMs depleted of 
the indicated transcripts and incubated in presence  and absence of ferric ammonium citrate (FAC). 
 
3.5 The RNAi screen identifies TLR6 as a novel regulator of ferroportin expression 
For in depth functional analyses I decided to focus on a single candidate. In my view, 
the most interesting identified FPN regulator was Toll like receptor 6 (TLR6), whose 
knockdown led to increased FPN levels. Toll like receptors are key components of the 
innate immune system thanks to their ability to recognize a variety of pathogen-
associated molecular pattern (PAMPs) such as bacterial cell-component like LPS, 
lipopeptides and double strands RNA of viruses. They are mainly expressed on antigen-
presenting cells, such as macrophages or dendritic cells where their signalling activates 
innate immunity. Thirteen TLRs (named simply TLR1 to TLR13) have been identified in 
humans and they are believed to function as dimers, most as homodimers. The 
increased FPN protein stability in the absence of TLR6 was further proven in bone 
marrow derived macrophages (BMDMs) obtained from TLR6-deficient mice (Figure 3.19 
A) clearly showing higher FPN levels. This effect occurred despite unchanged FPN and 
hepcidin mRNA levels (Figure 3.19 B, C), conclusively demonstrating that the lack of 
TLR6 affected FPN protein stability in a hepcidin-independent manner. 
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Figure 3.19 Identification of TLR6 as novel regulator of ferroportin protein expression. (A) Western-
blot analysis of endogenous FPN expression in BMDMs from wild type (WT) and TLR6-deficient mice 
(TLR6 KO); β-actin was used as loading control. (B, C) FPN and hepcidin mRNA levels were determined 
by qRT-PCR and calibrated to 36B4 mRNA levels. Data are means ± SEM, BMDMs were derived from 5 
mice per group, **P<0,01, Student’s t test. 
 
3.6 TLR2/6 stimulation reduces ferroportin expression in BMDMs 
The connection between iron and innate immunity is supported by several lines of 
evidence. Iron plays a central role in host-pathogen interaction (144). As most 
pathogens require iron for proliferation and full virulence, the innate immune system 
fights infections by sequestering iron in macrophages of the reticuloendothelial system. 
The resulting hypoferremia represents a major host defense strategy (145). As member 
of Toll-like receptor family, TLR6 is an inflammatory sensor which recognizes specific 
ligands via heterodimerization with TLR2 on the cell surface (146). I next wondered how 
its stimulation modulated FPN and iron regulation.  
I therefore took advantage of a synthetic lipoprotein ligand derived from Mycoplasma 
salivarium : FSL1 which was known to be recognized by TLR2/6 (147, 148) and to 
activate inflammatory response (147, 149). By treating BMDMs with different FSL1 
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concentrations, I observed a robust decrease in FPN mRNA levels at three different 
time points. This response was mediated by TLR6 because it was prevented (at short 
time point) or significantly blunted in TLR6-deficient BMDMs (Figure 3.20 A) as 
additionally confirmed by FPN protein analysis (Figure 3.20 B).  
The incomplete resistance to FSL1 in absence of TLR6 suggested the importance of 
TLR2 signaling for FPN expression and also indicated the existence of an additional 
route for this inflammatory signaling to control FPN levels. To test this hypothesis I 
analyzed FSL1-mediated FPN regulation in the absence of TLR2, the functional partner 
of TLR6. Its depletion completely abolished the FPN response (Figure 3.20 C) at all 
time points and even at high dose of FSL1, pointing at a central role of TLR2. In addition 
to TLR6, TLR2 was known to heterodimerizes also with TLR1, however I verified that 
TLR1-deficient BMDMs retained the responsiveness to FSL1 (Figure 3.21). Thus, taking 
together these results revealed that the FSL1-mediated regulation of FPN could be 
mediated by TLR2/6 hetero- and TLR2 homodimers.  
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Figure 3.20 TLR2/6 stimulation by FSL1 reduces ferroportin expression in BMDMs. (A) qRT-PCR 
analysis of FPN in BMDMs from WT and TLR6-deficient mice stimulated with FSL1(20ng/ml and 
100ng/ml) for the indicated time. Results are presented as a fold change ± SEM compared to untreated 
cells. (B) Western-blot analysis and quantification of FPN expression in BMDMs from WT and TLR6-
deficient mice treated with 100ng/ml FSL1 for 24h. β-actin detection ascertains equal sample loading. (C) 
qRT-PCR analysis of FPN in BMDMs from WT and TLR2-deficient mice treated with FSL1 (20ng/ml and 
100ng/ml) for 6, 12 and 24h. All data are reported as means ± SEM, BMDMs were derived from at least 4 
mice per group, *P<0,05, **P<0,01, ***P<0,001, Student’s t test. 
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Figure 3.21 TLR1-deficient BMDMs retain responsiveness to FSL1. qRT-PCR analysis of FPN in 
BMDMs from WT and TLR1-deficient mice stimulated with FSL1(20ng/ml and 100ng/ml) for the indicated 
time. Results are presented as a fold change ± SEM compared to untreated cells. All data are reported as 
means ± SEM, BMDMs were derived from at least 3 mice per group, *P<0,05, **P<0,01, ***P<0,001, 
Student’s t test. 
 
 
3.7 TLR2/6 and TLR4 ligand-specific stimulations similarly reduce ferroportin expression 
but differentially regulate hepcidin expression  
The suppression of FPN during inflammation was already reported in response to TLR4 
stimulation by LPS treatment (57, 90) and associated with a robust hepcidin production 
in neutrophils and macrophages (61). I compared FSL1 (TLR2/6) and LPS (TLR4) 
stimulation on BMDMs and observed that while they both triggered the expected FPN 
mRNA reduction, only LPS induced hepcidin mRNA (Figure 3.22). 
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Figure 3.22 FSL1-mediated TLR2/6 ligation reduces FPN expression in BMDMs without activating 
hepcidin mRNA expression. Ferroportin (A) and hepcidin (B) mRNA expression in BMDMs after FSL1 
and LPS (100ng/ml) stimulation. mRNA were normalized to 36B4 mRNA levels. All data are reported as 
means ± SEM, BMDMs were derived from at least 4 mice per group, *P<0,05, **P<0,01, ***P<0,001, , 
****P<0,0001 Student’s t test. 
 
To verify that both treatments induced an inflammatory response I then analyzed the 
IL1β, IL6 and TNFα mRNAs which all displayed increased expression, albeit 
quantitatively more moderately in FSL1-treated BMDMs (Figure 3.23). This finding 
suggested that increased expression of these cytokines per se was not sufficient for 
hepcidin activation. 
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Figure 3.23 FSL1 and LPS stimulation induce cytokines response. (A) IL1β, (B) IL6, (C) TNFα mRNA 
expression was assessed by qRT-PCR and calibrated to 36B4 mRNA levels in BMDMs derived from wild 
type mice and treated with FSL1 and LPS (100 ng/ml) for the indicated time. Data are means ± SEM, 
BMDMs were derived from at least 4 mice per group, *P<0,05, **P<0,01, ***P<0,001, Student’s t test. 
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I also extended the analysis to other bacterial lipopeptides, reported to activate TLR2-
dependent signaling: PAM3CSK4 and PamOct2C-(VPG)4VPGKG (148, 150). 
Interestingly FPN mRNA levels showed quantitatively similar decrease following all 
ligand stimulations (Figure 3.24 A), while persistent and considerable hepcidin induction 
was mediated only by LPS (Figure 3.24 D), further confirming the importance and the 
conservation of the FPN transcriptional response in the inflammatory context 
irrespective of hepcidin. TLR6 and TLR2-deficient BMDMs recapitulated and reinforced 
this result (Figure 3.24 E, F) suggesting almost null contribution of TLR2 challenge to 
hepcidin production in macrophage. In addition, the lack of TLR6 resulted in partial but 
enduring resistance only to FSL1 to trigger FPN suppression, while TLR2-deficient 
macrophages resulted unresponsive to all ligands, but LPS (Figure 3.24 B, C) 
confirming the independence of LPS signaling on TLR2. 
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Figure 3.24  Ferroportin and hepcidin regulation by TLR2 and TLR4-specific ligands in BMDMs. (A, 
B, C) Ferroportin mRNA expression was determined by qRT-PCR in wild type (WT) (A) TLR2-deficient 
(B) and TLR6-deficient (C) BMDMs stimulated with 100ng/ml TLR2-specific ligands (FSL1, PAM3CSK4, 
PamOct2C-(VPG)4VPGKG) and TLR4-specific ligand (LPS) for the indicated time. (D, E, F) Hepcidin 
mRNA expression was analyzed in the same samples. The mRNA quantification was calibrated to 36B4 
mRNA levels. All data are reported as means ± SEM, BMDMs were derived from at least 4 mice per 
group, *P<0,05, **P<0,01, ***P<0,001, ****P<0,0001, Student’s t test. 
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3.8 FSL1 and LPS injection induce hypoferremia in mice 
A common consensus in the field posits that hypoferremia during acute inflammation is 
caused by increased hepcidin expression. All the lines of evidence supporting so far the 
essential role to hepcidin in this process are mainly based on LPS injection in mice. 
Very different LPS concentration have been reported from 100 µg/mouse (90) to 5 
µg/mouse (70) all showing at different time points the link between hepcidin induction 
and serum iron level reduction.  
I decided to compare LPS and FSL1 in vivo response by injecting 11-weeks old mice 
with very low dose (25 ng/g bodyweight, corresponding to less than 1 µg per mouse) 
which I found sufficient to elicit hypoferremia already after 3 hours. Serum iron 
concentration and transferrin saturation were substantially lower compared to saline 
injection after both treatments (Figure 3.25 A, B). 
 
 
 
Figure 3.25 FSL1 and LPS injection induce hypoferremia in mice. Plasma iron levels and transferrin 
saturation were analyzed in wild type (WT) mice at 3h after saline (ctrl), FSL1, LPS injection. 25 ng of 
ligand per g bodyweight were used Data are means ± SEM. Results are representative of three 
independent experiments.  **P<0,01, Student’s t test. n= 6 mice per group. 
 
3.9 Hepcidin induction is not required to set acute hypoferremia in mice 
I next examined liver mRNA expression of FPN and hepcidin in response to FSL1 and 
LPS injections. Strikingly similar and robust FPN mRNA reduction was observed in both 
conditions while hepcidin up regulation resulted only in LPS injected mice (Figure 3.26 
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A, B). I also analyzed the expression of some inflammatory cytokines, such as TNFα 
and IL6, which were induced only in LPS treated samples. In particular IL6, the well-
characterized inflammatory activator of hepcidin, was not significantly increased by 
FSL1 injection (Figure 3.26 C, D). Despite these differences, hepatic iron measurement 
revealed similar levels of iron retention (Figure 3.26 E) and FPN protein quantification 
displayed significant reduction in both conditions (Figure 3.26 F). 
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Figure 3.26 Hepatic hepcidin induction is not required to set acute hypoferremia in mice. (A, B, C, 
D) Hepatic FPN, hepcidin, TNFα and IL6 mRNA expression were determined by qRT-PCR and calibrated 
to 36B4 mRNA levels. € The hepatic non-heme iron content was quantified as indicated. (F) Western-blot 
analysis and quantification of FPN expression in the liver of the injected mice. β-actin was used as 
loading control. Data are means ± SEM. Results are representative of three independent experiments. 
*P<0,05, **P<0,01, ***P<0,001, Student’s t test. n= 6 mice per group. 
 
Parallel analysis of the spleen showed FPN decrease at mRNA (Figure 3.27 A) and 
protein level even in this tissue (Figure 3.27 C, D). In particular, the FPN protein 
reduction resulted even more pronounced in magnitude in isolated splenic 
macrophages (Figure 3.27 E) which were expected to be recruited in the tissue during 
inflammation. Hepcidin induction in the spleen has been already reported (61, 151) in 
consequence of pathogen and LPS challenge. Consistently, I observed an increasing 
tendency in LPS injected mice, although hepcidin is generally low expressed in this 
tissue. As predicted from the experiments in BMDMs, splenic hepcidin mRNA 
expression was unchanged following FSL1 injection (Figure 3.27 B).  Consistent with 
the findings in the liver, non heme iron content and Perl’s Prussian staining 
demonstrated iron accumulation in the spleen with a similar pattern upon the two ligand 
injections (Figure 3.27 F).  
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Figure3.27 Splenic ferroportin down regulation in the hypoferremic response does not require 
hepcidin contribution. (A, B) FPN and hepcidin, expression was assessed by qRT-PCR  in WT mice at 
3h after saline (ctrl), FSL1, LPS injection. (C, D) Western-blot analysis and quantification of FPN 
expression in the whole spleen and E in the splenic macrophages isolated from the injected mice. β-actin 
was used as loading control. (F) The splenic non-heme iron content was determined in the same groups 
of mice. DAB-enhanced Perls’ iron staining shows iron retention in the spleen of FSL1 and LPS injected 
mice as compared to ctrl. Data are means ± SEM.*P<0,05, **P<0,01, ***P<0,001, Student’s t test. n= 6 
mice per group. 
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Inflammatory cytokines were induced by both treatments, even though to a different 
extent. In particular TNFα and IL6 mRNA expression levels are here showed (Figure 
3.28 A, B). On the other hand I could not observe any significant changes in hepatic or 
splenic TfR1 mRNA levels (Figure 3.28 C, D) whose decrease in response to IRPs 
inactivation when iron levels are high (93) is likely to require more time. 
 
 
 
Figure 3.28 TNFα, IL6, TFR1 mRNA expression in the spleen of mice injected with FSL1 and LPS. 
Splenic mRNA level of TNFα and IL6 (A, B) and hepatic and splenic TFR1 mRNA levels (C, D) were 
measured by qRT-PCR and calibrated to 36B4 mRNA levels in wild type mice after 3hs injection with 
saline (ctrl), FSL1, LPS. Data are means ± SEM.*P<0,05, **P<0,01, ****P<0,0001, Student’s t test. n= 6 
mice per group. 
 
The crucial role of hepcidin in setting hypoferremia during acute inflammation has been 
recently questioned by LPS injection in hepcidin knockout mice. Regardless the lack of 
hepcidin these mice were shown to have reduced serum iron level upon the treatment, 
suggesting the possibility that hypoferremia during acute inflammation involves 
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hepcidin–independent routes. The LPS-induced hypoferremia was attributed to 
diminished dietary iron absorption due to decreased duodenal FPN and DMT1 mRNA 
expression (152). Following this lead I examined the duodenal expression of these iron 
transporters but I found that the duodenal mRNA expression of FPN and DMT1 was 
unchanged in FSL1-injected mice and I observed a trend towards decreased FPN and 
DMT1 mRNA levels upon LPS injection (Figure 3.29 A, B). Furthermore Perl’s Prussian 
blue staining showed no altered iron distribution, confirming that iron acquisition was not 
impaired in the two inflammatory conditions (Figure 3.29 C)  
 
 
 
Figure 3.29 Iron absorption is not altered upon FSL1and LPS injection. (A, B) Ferroportin and 
divalent metal transporter 1(DMT1) mRNA expression were assessed in the duodenum of wild type mice 
at 3h after saline (ctrl), FSL1, LPS injection. Data are means ± SEM. *P<0,05, Student’s t test, n=6. (C) 
DAB-enhanced Perls’ iron staining reveals no impaired iron distribution in the duodenum of inflamed mice 
compared to wild type. 
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Recent lines of evidence have also pointed out a novel role of HFE in the inflammation-
induced hypoferremia. In particular LPS injection was shown to lead to a rapid HFE 
protein reduction in the spleen which, according to the authors, explained iron retention 
and consequently, plasma iron decrease (153). I therefore analyzed HFE mRNA levels 
in the spleen and in the liver of mice injected with FSL1 and LPS and I observed that 
they decreased in the spleen upon both treatments (Figure 3.30 B) while they appeared 
to be differentially regulated in the liver (Figure 3.30 A), showing opposite trend in 
consequence of LPS injection. However I could not apply protein analysis in these 
tissues, as the antibody anti-HFE used in the mentioned report did not show a proper 
protein recognition and no other functional antibodies were commercially available at 
the moment. 
 
 
Figure 3.30 HFE  mRNA regulation in liver and spleen of mice injected with FSL1 and LPS. HFE 
mRNA level were analyzed by RT-qPCR in the liver (A) and in the spleen (B) of wild type mice injected 
with FSL1 and LPS (25 ng/g) for 3h. The data are normalized on 36B4 mRNA levels and are represented 
as means ± SEM. *P<0,05, ***P<0,001, ****P<0,0001 Student’s t test, n=6. 
 
To confirm directly that FSL1-induced hypoferremia and FPN regulation are 
independent of hepcidin-FPN interaction in vivo, I ultimately took advantage of a 
recently published mouse model available in the lab containing a C326S mutation in 
endogenous ferroportin which causes full resistance to hepcidin binding and response 
in vivo (190). Preliminary experiments showed that BMDMs derived from these mice 
responded to FSL1 and LPS as BMDMs derived from wild type mice, down regulating 
FPN mRNA and protein levels (Figure 3.31 A, E) and inducing cytokine expression, 
such as TNFα and IL6 (Figure 3.31 C,D). As for wild type BMDMs, hepcidin resulted 
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strongly up regulated only upon LPS stimulation (Figure 3.31 B). In vivo experiments 
further corroborated these findings and demonstrated that despite high iron levels that 
accumulate in these mice, FSL1 efficiently reduced serum iron levels 3 hours after 
injection (Figure 3.32 A). Most importantly FPN mRNA and protein levels were 
significantly reduced in the liver and in the spleen (Figure 3.32 B, C) in the absence of a 
significant hepcidin contribution. 
 
 
Figure 3.31 BMDMs derived from FPN
C326S 
knock-in mice down regulate FPN in response to FSL1 
and LPS. (A, B, C, D) Bone marrow derived macrophages were derived from wild type mice (WT) and 
from FPN
C326S 
knock-in mice (FPNC326S) and stimulated with FSL1 and LPS (100ng/ml) for 24 hours. 
Ferroportin (A), hepcidin (B), TNFα (C) and IL6 (D) mRNA levels were analyzed by RT-qPCR and 
normalized to 36B4 mRNA levels.( E) FPN protein levels were analyzed by Western-blot in BMDMs 
untreated or treated with FSL1 and LPS as indicated. β-actin was used as loading control.  BMDMs were 
derived from 3 mice per group. Data are means ± SEM.*P<0,05, ***P<0,001, Student’s t test.  
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Figure 3.32 FSL1 injection in FPN
C326S 
knock-in mice induces hypoferremia. (A) Plasma iron level 
was measured in FPN
C326S 
knock-in mice injected with FSL1 (100 ng/g bodyweight) per 3h. Splenic (B, C) 
and hepatic (D, E) ferroportin mRNA and protein levels were analyzed by qRT-PCR and Western-blot in 
the same groups of mice. β-actin was used as loading control. Data are means ± SEM.*P<0,05, **P<0,01, 
***P<0,001, Student’s t test. n= 6 mice per group. 
 
3.10 Investigating the TLR2/6 mediated ferroportin transcriptional regulation 
FPN mRNA reduction induced by Toll like receptor ligation appeared to be essential to 
set the hypoferremia during acute inflammation. However little is known about the 
molecular basis of this process. In the attempt to investigate this aspect diverse 
approaches were applied. 
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3.10.1 Testing cytokine stimulation 
Controversial results were reported on the direct and indirect role of inflammatory 
cytokines to modulate FPN levels. In particular, the importance of TNFα for FPN 
regulation has been highly debated (90, 91). To better understand its role I treated 
BMDMs with different concentration of recombinant IL1β, IL6 and TNFα and I analyzed 
FPN mRNA level at three different time points. As shown in figure 3.33 only TNFα 
induced strong FPN down regulation even after short incubation time and at low dose. 
This result may suggest a role of TNFα in reducing FPN expression. In support of this I 
also observed that in TLR6- deficient BMDMs TNFα was not induced 6h after FSL1 
treatment, the same time point at which I observed no change in FPN mRNA level 
(Figure 3.33 D). The same did not apply to IL1β and IL6 (Figure 3.33 E). 
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Figure3.33 TNFα stimulation induces FPN mRNA reduction in BMDMs. BMDMs were stimulated with 
TNFα (A), IL1β (B) and IL6 (C) at the indicated concentrations. FPN mRNA levels were analyzed after 6h, 
12h and 24h by RT-qPCR and calibrated to 36B4.TNFα (D) and, in addition, IL1β and IL6 (E) mRNA 
expression was measured in BMDMs derived from wild type (WT) and TLR6-deficient mice (TLR6 KO) 
after 6h of FSL1 treatment. Data are means ± SEM, BMDMs were derived from at least 4 mice per group, 
*P<0,05, **P<0,01, ***P<0,001, ****P<0,0001 Student’s t test. 
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3.10.2 Testing specific inhibitors of TLRs pathway 
To investigate the molecular pathways triggering FPN suppression as a consequence of 
inflammatory stimuli I applied specific inhibitors for signaling molecules and kinases that 
could be involved in the process. Following ligand recognition, TLR2 heterodimers were 
known to initiate a MyD88-dependent pathway which ultimately induced nuclear 
translocation of nuclear factor-B (NFkB) to modulate gene transcription. In addition MAP 
kinases were reported to mediate JNK and p38 activation which triggered the induction 
of the transcription factor activation protein 1 (AP-1) to control gene transcription of 
cytokines and other molecules (154, 155). Further studies in human macrophage cell 
lines also demonstrated, by using specific inhibitors, that phosphatidylinositol-3 kinase 
(PI3K) and AKT played a role in the TLR-mediated induction of cytokines (149, 156, 
157) and that tyrosine phosphorylation by Src kinases was required for TLRs activation 
(157-159).To better dissect the molecular mechanism leading to TLR-mediated FPN 
regulation I tested several inhibitors which specifically targeted key elements of the TLR 
signaling pathway (Table 3.1 and figure 3.34) on BMDMs challenged with FSL1. 
Inhibitor Target 
LY294002/ Wortmannin PI3K kinase inhibitors 
 
PP1/Saracatinib/Bafetinib c-Src inhibitors 
Abl/Lyn inhibitor 
SB202190 /SP600125 P38-MAPK and JNK inhibitor 
UO126 MEK1/2 inhibitors 
PDTC/SN50  NFKB activation/ translocation 
 inhibitors 
 
Table 3.1 Inhibitors of TLR signaling pathway tested on BMDMs. 
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Adapted from Oliveira-Nascimento et al., Frontiers in Immunology, 2012 
Figure 3.34 Inhibition of key components of the TLR2 signaling. After ligand recognition, TLR2 
heterodimerizes with TLR1 or TLR6. Activation of the signal requires the phosphorylation of TLR2 
cytosolic domain by Src. TIR domain of TIRAP binds the TIR domain of TLR2 and recruits the adaptor 
protein MyD88. IRAKs are then recruited and IRAK 4 phosphorylates (P) IRAK1, which then mediates 
auto-phosphorylation to activate TRAF6. Since IRAK1 is rapidly degraded, IRAK2 also activates TRAF 6 
in latter responses. Ubiquitinated (U) TRAF6 triggers the activation sequence TAB2 – TAK1 – IKK 
complex which ultimately leads to IκB phosphorylation and ubiquitination by the IKK complex. IkB 
degradation then releases NF-κB to translocate to the nucleus and activate gene transcription. In parallel, 
TAK1 also activates MKK6 for subsequent JNK and p38-mediated AP-1 activation that triggers gene 
transcription of cytokines and accessory molecules. MyD88, myeloid differentiation primary-response 
gene 88; TIRAP, TIR adaptor protein; IRAK, interleukin-1 receptor associated kinase; TRAF, TNF 
receptor associated factor; TAK, transforming growth factor beta-activated kinase 1; TAB, TAK1-binding 
protein; MKK/JNK/P38, MAP kinases, NEMO/IKKs, kinase complex; NF-κB, nuclear factor-κB; IκB, kinase 
complex; AP, activator protein; PI3K, phosphatidylinositol-3 kinase, RIP2, receptor interacting protein 
2;RAC1, ras-related C3 botulinum toxin substrate 1. Inhibitors and their targets are indicated. 
Interestingly I observed that the inhibition of the PI3K (by LY294002 and Wortmannin) 
and the Src kinases (by PP1 and Saracatinib) led to FPN mRNA increase irrespectively 
of any additional treatment (Figure 3.35 A, B). As a positive control I analyzed the 
decreased phosphorylation of AKT for PI3K inhibitors and Tyr416 which is the auto-
phosphorylated on active Src. In particular LY294002 appeared to induce strong FPN 
protein up regulation after 24h treatment (Figure 3.35 C), although the phosphorylation 
of its target (AKT) recovered already within few hours from the treatment. On the other 
hand, the inhibition mediated by the other PI3K inhibitor Wortmannin was visible even 
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after 24h (Figure 3.35 D), but FPN protein levels displayed no increase. This suggested 
that LY294002 altered FPN expression in a PI3K-independent manner. 
 
Figure3.35 PI3K and Src kinase inhibitors increase FPN expression in BMDMs. (A, B) FPN mRNA 
level were analyzed after 6h treatment with the indicated inhibitors. Western blot analysis ascertains 
specific target inhibition of AKT phosphorylation for PI3K inhibitors (A) and Tyr416 phosphorylation for Src 
kinase inhibitors (B). (C) FPN mRNA and protein level were evaluated after 24h treatment with the 
indicated PI3K inhibitors. (D) Inhibition of AKT phosphorylation results stable till 24h Wortmannin 
treatment. β-actin was used as loading control. Data are means ± SD from 3 independent experiments, 
**P<0,01, Student’s t test. 
None of the inhibitors I tested completely prevented the FSL1-mediated FPN reduction. 
However while FSL1 treatment completely overrode the effect of Src inhibitors on FPN 
mRNA levels (which return comparable to the levels of untreated sample) (Figure 3.36 
C, D) PI3K inhibition, and in particular LY294002 pre-treatment, yet displayed higher 
FPN expression (Figure 3.36 A, B).  
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Figure 3.36 PI3K inhibitors reduce the FPN decrease induced by FSL1. BMDMs were incubated with 
PI3K inhibitors (LY294002 and Wortmannin) (A, B) or Src kinase inhibitors (PP1 and Saracatinib) (C, D) 
for 30 minutes before the addition of FSL1 (100ng/ml). After 6h FPN mRNA levels were analyzed by RT-
qPCR and calibrated to 36B4 mRNA levels. Data are means ± SD from 3 independent experiments, 
*P<0,05, **P<0,01, ***P<0,001, Student’s t test. 
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4. DISCUSSION AND PERSPECTIVES 
4.1 Unresolved and controversial aspects of ferroportin regulation 
The maintenance of systemic iron homeostasis plays a pivotal role in human health. 
Iron overload and deficiency diseases belong to the most common pathologies across 
the globe. Systemic iron homeostasis evolved to maintain a plasma iron concentration 
that ensures sufficient iron supplies to organs while preventing iron overload. This 
regulatory mechanism is executed through the interaction between the hepatic hormone 
hepcidin and the sole known iron exporter ferroportin (FPN). FPN is predominantly 
expressed in tissues that supply iron to plasma, such as hepatocytes, duodenal 
enterocytes, macrophages and placental trophoblasts. Hepcidin binds to FPN and 
induces its internalization and degradation, reducing cellular iron export and thereby 
regulating mobilization of iron from hepatic stores, dietary iron absorption, iron release 
from macrophages and iron transfer across the placenta. Misregulation of the 
hepcidin/FPN system causes diseases of iron overload (e.g. hereditary 
hemochromatosis) and iron deficiency (e.g. the anaemia of chronic inflammation), two 
of the most frequent disorders worldwide. 
FPN was identified as the receptor for hepcidin in 2004. An engineered HEK293 cell line 
expressing the FPN-GFP fusion protein was shown to bind hepcidin and mediate FPN 
degradation in lysosomes (28). Following mechanistic studies in the same cellular 
system then claimed that phosphorylation and ubiquitination were crucial modifications 
to induce the internalization and degradation of FPN (97). In particular mutations at 
specific tyrosine residues (302, 303) in FPN and the treatment with Src kinase inhibitor 
PP2 were reported to prevent the hepcidin-mediate phosphorylation of FPN at the 
plasma membrane. Furthermore by using JAK2-deficient cells and siRNA approaches 
De Domenico et al. proposed that JAK2 was the kinase responsible for FPN 
phosphorylation and that the dimerization of FPN monomers was required for JAK2 
activation (98). However several papers from these authors were retracted (188, 189) 
and a more recent report has demonstrated that neither JAK2 nor phosphorylation of 
the tyrosine residues was necessary for the post translational control of FPN (99). In 
particular FPN mutants for several tyrosine residues were proven to retain 
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responsiveness to hepcidin and FPN internalization was shown to be preserved in JAK2 
null cells as well as in cells treated with Pan-Jak and JAK2-selective inhibitors. In 
addition, hepcidin treatment did not result in the activation of JAK2-STAT signaling and 
in vivo JAK2 inhibition did not prevent the reduction of serum iron levels normally 
observed by hepcidin administration. While these lines of evidence have conclusively 
disproven the role of JAK2 and phosphorylation for FPN regulation, ubiquitination has 
been further shown to be the relevant modification required for FPN endocytosis (100). 
Hepcidin addition induced FPN ubiquitination within 5 minutes in HEK293 engineered 
cell lines as well as in primary bone marrow derived macrophages. Consistently, 
mutations of lysine residues in the third intracellular loop of FPN impaired its hepcidin-
mediated endocytosis and, consequently the ability of cells to retain iron. This finding 
also seemed to explain the mild iron overload observed in a patient carrying a mutation 
in heterozygosity at the lysine residue 240 of FPN which was expected to cause at least 
partial resistance to hepcidin in vivo.  
RNA interference approaches in a HEK293 cell line expressing a FPN-GFP fusion 
protein suggested that a clathrin-dependent process controls FPN internalization. In 
particular depletion of epsin, a protein required for clathrin-mediated endocytosis, was 
reported to inhibit the FPN degradation following hepcidin addition (97). Different 
conclusions were drawn by Auriac et al. in murine macrophages by using drug inhibitor 
strategies (101). In particular, FPN expression was demonstrated to localize in specific 
detergent-resistant membrane compartments containing raft markers, such as caveolin 
and flotillin. The integrity of the raft was required for the hepcidin control of FPN, as the 
lipid raft breakdown caused by two drugs (filipin and methyl-β-cyclodextrin) through the 
sequestration of cholesterol, affected the endocytosis and degradation of FPN in 
BMDMs and macrophage cell lines. On the other hand the inhibition of clathrin-
dependent endocytosis by another drug (chlorpromazine) did not cause any alteration in 
the hepcidin-mediated FPN regulation, suggesting that clathrin-independent 
mechanisms mediated FPN internalization in macrophages. Such a discrepancy has 
suggested the existence of new and yet not defined cellular pathways controlling the 
hepcidin-dependent FPN endocytosis, although different cell types and different 
experimental procedures were used in the described works.  
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A second route of FPN internalization independent of hepcidin has also been 
characterized in a HEK293 engineered cell line in response to cytosolic iron depletion or  
activity reduction of the multicopper oxidase ceruloplasmin (141). Under these 
conditions the ubiquitination of FPN by the E3 ubiquitin ligase Nedd4-2 and its 
accessory protein Ndfip-1, was shown to induce FPN internalization from the plasma 
membrane to protect cells from iron depletion and apoptosis. This hepcidin-independent 
degradation pathway was proposed to be an ancestral conserved mechanism that has 
preceded the hepcidin-dependent FPN endocytosis as supported by additional data in 
the invertebrate Caenorhabditis elegans. In this organism FPN protein lacks the critical 
cysteine residues required for hepcidin binding, however iron deprivation induced its 
internalization despite the absence of hepcidin contribution. Although the authors 
continue endorsing the validity and the conclusions of the study, this publication has 
been retracted because of a number of errors declared in the figures (188). 
 
4.2 Rationale of the study 
High throughput RNA interference has been used over the last years as a powerful 
technology to reduce expression levels of specific genes and learn about their potential 
functions in a defined biological process. Thus, the goal of my PhD project was to 
identify genes that control or modify the hepcidin-dependent FPN internalization by 
applying an RNAi screen. The importance of FPN phosphorylation upon hepcidin 
binding appeared to be well established at the beginning of my PhD. However the 
discovery of new molecular details in primary cells already began to challenge the 
model proposed for FPN internalization and degradation (Figure 1.5). At this stage the 
role of kinases and related signalling molecules was expected to be essential for the 
post transcriptional regulation of FPN stability and, therefore it was of priority interest to 
apply an RNAi screen focused on kinases. 
 
4.3 A focused RNAi screen identifies hepcidin-independent ferroportin regulators 
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HeLa cells were already reported to support hepcidin-mediated FPN internalization from 
expressed reporter genes (28) and robust protocols of reverse transfection of cells on 
siRNA arrays for these cells were available (137, 139). For these reasons the screening 
was applied to a stable and inducible HeLa cell line expressing a hFPN-Rluc fusion 
protein. The quantification of the Rluc reporter activity in the assay provided a fast, 
quantitative simple and sensitive read-out of FPN expression and regulation. However it 
precluded the visualization and the quantitative analysis of intermediate FPN 
internalization steps or cell viability alterations which, in principle, could have been 
monitored by a cell-imaging based approach. For the screen I used a pool of 4 siRNA 
sequences per gene. This approach in principle promises a greater phenotypic 
penetrance, while raising the risk of possible off-target effects. One way to enhance 
confidence in the screening results was the identification of possible siRNA-mediated 
side effects regulating the reporter gene only rather than FPN. I therefore took 
advantage of a HeLa cell line with stable and inducible expression of the Rluc protein 
that was generated in an identical manner and subjected to the same screening 
strategy. By this approach I excluded those siRNAs which altered Rluc expression per 
se from the follow-up analysis.  
Unexpectedly, the screening yielded many candidates which potentially controlled FPN 
protein stability in a hepcidin-independent manner and identified only few genes 
involved in the hepcidin-induced FPN internalization pathway (Figure 3.17). Importantly, 
the depletion of JAK2 kinase did not result in significant alteration of the FPN-Rluc 
regulation after hepcidin treatment, excluding it from the hit list and further questioning 
its role in the FPN internalization process. This finding is consistent with the evidence 
accumulated during the last years (previously discussed) that disproved the importance 
of phosphorylation for the hepcidin-mediated FPN regulation. The usage of a focused 
library, mainly containing kinases, limited functional association analysis among the 
candidates and precluded the identification of shared pathways. However, 14 potential 
FPN regulators were associated with immune processes. The relationship between iron 
and immunity plays a critical role during pathogen infection (see paragraph 4.4) and this 
made these candidates interesting for further analysis. 
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Engineered cell lines have been extensively used to investigate molecular mechanisms 
underlying hepcidin-mediated FPN regulation. Although they represent a powerful tool 
to dissect molecular signalling by applying high throughput techniques, they do not fully 
recapitulate the physiological regulation of FPN which plays its essential role in 
specialized cell types, such as macrophages or enterocytes. 
In this project results obtained in HeLa cells needed to be validated in a more 
physiological system. Technical limitation was the lack of an effective antibody which 
recognizes the human FPN protein. Human and mouse FPN share 95% of homology 
and the mechanisms mediating FPN regulation are expected to be highly conserved 
between these two species. Macrophages express high levels of FPN and constitute the 
primary site of body iron turnover, playing a major role in ensuring adequate plasma iron 
levels. In addition, for their functions as scavengers, antigen presenting cells and 
secretory cells, they are vital to the regulation of immune responses and the 
development of inflammation. For these reasons I chose to further validate the role of 
the identified putative FPN regulators in murine bone marrow-derived macrophages, 
focusing on the genes related to immune processes. The mRNA expression of some 
mouse homologs of putative FPN regulators (TEX14, BLNK, MECOM, ADAM9, EPHB6) 
was very low or undetectable in BMDMs, preventing their characterization. For others 
(BMP2K, IPMK, PHKA1, ITPKB, TLR6) I could confirm the screening results by 
observing an increase in FPN protein levels despite the limited quality of the anti-FPN 
antibody used for Western-blot detection. Among them, ITPKB (inositol-trisphosphate 3-
kinase B) and IPMK (inositol polyphosphate multikinase) are known to be involved in the 
inositol phosphate metabolism. These kinases both mediate the phosphorylation of the 
second messenger inositol 1,4,5-trisphosphate to Ins(1,3,4,5)P4 which is important for 
cellular signaling and, in particular, in the control of Ca2+ release from intracellular 
stores (160-162). Studies in humans demonstrated that Ca2+ supplementation can have 
short-term inhibitory effects on iron absorption (163-166). In addition Ca2+ treatment of 
human intestinal Caco-2 cells was reported to decrease FPN abundance at the 
basolateral membrane and increase cellular iron retention within 1.5 hour, although this 
effect was of short duration and adaptation  occurred with time (167). Taking together 
these data may suggest that the depletion of inositol phosphate kinases could alter FPN 
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expression levels because of changes in intracellular Ca2+ concentration. However this 
hypothesis was not investigated further in this work and remains to be tested by 
additional experiments. 
For its well-established role in pathogen recognition and innate immunity activation I 
rather decided to focus on TLR6 for further functional analysis. 
4.3.1 TLR6 is a novel regulator of ferroportin protein expression 
Toll like receptors (TLRs) 1, 3, 4 and 6 were present in the siRNA library used for the 
screening. Among them only TLR6 was identified and validated as a putative ferroportin 
repressor. Its key role in the innate immune system and the tight relationship between 
iron and host defense, made it the most interesting candidate to better characterize in 
macrophages. The availability of BMDMs deficient for TLR6 allowed me to confirm the 
finding from HeLa cells overcoming all the technical limitations that I faced analyzing the 
effects of transient transcript depletions (page 75-76). Furthermore the increase of FPN 
protein levels independent of alterations in ferroportin and hepcidin mRNA levels 
corroborated that the lack of TLR6 affected FPN protein stability irrespectively of 
hepcidin contribution (Figure 3.19). 
The responsible mechanism was not addressed in this work, however it is possible to 
imagine that under basal conditions TLR6 reduces or maintains low FPN protein levels 
indirectly, perhaps modulating the protein turnover. TLRs mostly play a role under 
inflammatory conditions which are known to modulate iron homeostasis. Therefore I 
chose to explore FPN regulation following TLR6 ligation and activation, mimicking a 
pathogen-induced inflammatory response. 
 
4.4 Battle for iron 
Iron is a central player for host-pathogen interactions. It is an essential nutrient for both 
humans and pathogens and it is required to allow for microbial proliferation and to 
achieve full virulence. Given its relevance for microbe survival, an important response of 
the innate immune system has evolved to limit iron availability to invading pathogens. 
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The fact that pathogens developed a number of mechanisms to acquire host iron and 
the attempt of the host to withhold iron as defence, has generated an ever-evolving 
battleground for this metal. Bacterial pathogens employ several systems to satisfy iron 
requirements (Figure 4.1). Among them, siderophores are small iron chelating 
compounds secreted by microorganism under conditions of low-iron availability, which 
bind to soluble Fe3+ with high affinity (168). A special example is represented by 
mycobactins, the lipophilic siderophores of mycobacteria which chelate intracellular iron 
in macrophages. Mycobactins accumulate in macrophage lipid droplets that can diffuse 
out of phagosome to capture cytoplasmic iron (169). Many pathogens, including fungi, 
have also developed the ability to acquire iron from heme via direct heme uptake (most 
Gram-positive bacteria) or hemophore-dependent mechanisms (e.g. B.anthracis) which 
allow for the extraction of heme groups from host hemoprotein, such as hemoglobin 
(170). Alternatively, microorganisms like Neisseria gonorrhoeae under iron-limiting 
conditions can express transferrin or lactoferrin binding proteins on the membrane to 
directly internalize transferrin- or lactoferrin-bound iron (171). 
During infection the innate immune system counteracts pathogen iron uptake by limiting 
local and systemic iron availability. Local iron sequestration at infectious foci is mainly 
achieved by lactoferrin and siderocalin production. Lactoferrin is a host glycoprotein with 
antimicrobial activity contained in mucosal secretions and in secondary granules of 
neutrophils and, like transferrin, has the capacity to bind free iron with high affinity (172). 
Siderocalins, also known as neutrophil gelatinase-associated lipocalins, are produced 
by neutrophils during acute infection and neutralize pathogen iron intake by 
sequestering the siderophores released from pathogens (173). Systemically, the 
inflammatory response triggered by the innate immune system alters the expression of 
several iron-related genes, resulting in the sequestration of iron in macrophages of the 
reticuloendothelial system and in reduced serum iron levels. The hypoferremia induced 
during infection is a major host defence strategy and it was first observed in the forties 
following Staphylococcus aureus inoculation and turpentine injection (174). It seems 
well established that the crucial effector of this response is hepcidin whose release from 
the liver is known to be induced by inflammatory stimuli (paragraph 1.5.4). Hepcidin 
induction provokes FPN protein decrease and, consequently, tissue iron retention thus 
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explaining the drop in serum iron levels. However, in addition to the FPN post-
translation regulation mediated by hepcidin, infectious agents were also reported to 
reduce FPN mRNA levels (57, 90), suggesting that different mechanisms can modulate 
FPN levels during infection. 
 
 
                            Gram-positive                                                      Gram-negative 
Adapted from Cassat and Skaar, Cell Host Microbe, 2013 
Figure 4.1 Pathogen iron uptake strategies. (A) Gram-positive microorganisms can acquire iron from 
heme through heme and hemoprotein receptors or through the release of hemophores . Heme is then 
transported into the cytoplasm by ABC-type transporters and degraded by heme oxygenase to extract 
iron. Alternatively, under low-iron conditions pathogens secrete siderophores which capture extracellular 
iron and then re-enter the cell through specific transporters. (B) In addition to these iron acquisition 
systems, some Gram-negative microorganisms also express transferrin or lactoferrin binding proteins 
(TBP/LBP) to acquire transferrin(TF)-  or lactoferrin(LF)- bound iron. The transport of heme, siderophore-
iron or transferrin-iron  complexes across the Gram-negative outer membrane requires energy generated 
from the TonB/ExbB/ExbD system.  
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4.5 Ferroportin mRNA down regulation is a conserved response to pathogen infection 
FPN is one of the iron-related genes whose expression is altered in consequence of 
immune system activation, for instance during pathogen invasion. Its reduction is one of 
the defense mechanisms evolved to diminish iron supply to pathogens. Yang et al., in 
2002 and Liu et al., in 2005 demonstrated that LPS stimulation of splenocytes induced 
TLR4-dependent reduction of FPN mRNA and protein, in a hepcidin-independent and 
dependent manner, respectively. My data showed that TLR6 ligation with FSL1 
decreased FPN levels in bone marrow derived macrophages (Figure 3.20, A, B). 
However, in this case, even the protein reduction occurred independently of hepcidin as 
I did not observe an increase in hepcidin expression following FSL1 stimulation (Figure 
3.22 B). FPN mRNA expression responded with a quantitatively similar decrease to 
other bacterial lipopeptides (PAM3CSK4 and PamOct2C-(VPG)4VPGKG) (Figure 3.24) 
known to activate TLR2 which is the functional partner of TLR6 (148, 150). These 
results, in addition to the reported FPN decrease in consequence of other bacterial, 
fungi and virus components (153, 175), together indicated that this is an important and 
conserved transcriptional response in the inflammatory context. However under defined 
conditions the control of FPN and hepcidin expression can be uncoupled as the 
decrease of FPN levels downstream of TLR2/6 signaling was independent of hepcidin 
activation. This conclusion is in contradiction to the data published by Layoun et al. in 
2012 by using the RAW264.7 cell line and peritoneal macrophages challenged with 
several bacterial cell wall constituents (176). However in my hands, RAW264.7 cells did 
neither show FPN mRNA down regulation nor hepcidin mRNA induction following FSL1 
treatment, despite increased cytokine expression. The reason of such discrepancy 
remains unclear, nevertheless my data suggest that this cell line may not represent a 
proper system for the study of the inflammatory-mediated FPN regulation. 
4.5.1 TLR2/6 heterodimers and/or TLR2 homodimers mediate ferroportin response to 
FSL1 
The specific activation of TLR6 can be achieved by ligation with Mycoplasma fermentas 
derived lipopeptides other than FSL1, like the macrophage-activating lipopeptide 2 
(MALP-2). TLR6-depleted peritoneal macrophages were reported to be unresponsive to 
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MALP-2 (177). To test the specificity of FSL1 for TLR6 and the dependency of FPN 
response on it, I analyzed the FPN mRNA regulation in TLR6-deficient BMDMs. 
According to the identity of framework structure between FSL1 and MALP-2 I expected 
FSL1-mediated FPN down regulation not to occur in absence of TLR6. Conversely I 
showed that the FPN mRNA down regulation was partially dependent on TLR6, 
because it was prevented only at 6h time point and significantly blunted at later time 
points (Figure 3.20 A, B). Rather, TLR2 played a further role in this regulation, as in 
TLR2-deficient BMDMs the FSL1-mediated control of FPN was completely abolished 
(Figure 3.20 C). TLR2 is known to form heterodimers with TLR6 and TLR1 (146). The 
existence of these different heterodimers expand the ligand spectrum enabling the 
innate immune system to recognize different lipopeptide but it does not seem to lead to 
differential signaling (148). It is assumed that diacylated lipopeptide, such as FSL1 or 
MALP-2, signal through TLR2-TLR6 heteromers, whereas triacylated lipopeptide, such 
as PAM3CSK4, induce signaling through TLR2-TLR1 heteromers (178). However 
investigations with new synthetic lipopeptide derivates have shown that this distinction 
is not clear-cut  and some lipopeptide are recognized by TLR2 in a TLR1- and TLR6-
independent manner, indicating that TLR2 might be able to signal as homomers (150, 
179). I demonstrated that TLR1 was not involved in the FSL-1 controlled FPN response, 
as TLR1-deficient BMDMs retained their responsiveness to FSL1 (Figure 3.21). Thus, 
taken together my results revealed that FSL1-mediated FPN regulation can be 
mediated by TLR2/6 heterodimers and/or TLR2 homodimers. Such redundancy may 
enable the immune system to trigger a more immediate and robust response to rapidly 
reduce iron supply to pathogens. 
While FSL1-triggered FPN suppression depended on TLR2 and TLR6, the FPN 
response mediated by PAM3CSK4 and PamOct2C-(VPG)4VPGKG only depended on 
TLR2 signaling (Figure 3.24 A, B, C). Conversely, as expected (61), LPS stimulation 
reduced FPN and induced hepcidin mRNA expression throughout the time-course that I 
applied by mechanisms that were independent on TLR2 and TLR6 (Figure 3.24 D, E, 
F). 
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In this work FPN mRNA reduction resulted a conserved response to TLR2 (FSL1, 
PAM3CSK4, PamOct2C-(VPG)4VPGKG) and TLR4 (LPS) ligation while hepcidin 
mRNA expression appeared to be mainly mediated by TLR4 activation (61). This may 
suggest that FPN transcriptional reduction represents the key mechanism shared 
between all TLRs to restrict iron export and that hepcidin induction in macrophages is a 
secondary event maybe triggered by specific pathogens. 
4.6 The importance of hepcidin induction in macrophages 
In addition to hepcidin production in the liver, several infectious agents were also 
reported to induce hepcidin synthesis in neutrophils and macrophages. The first 
evidence of hepcidin induction in macrophages was reported in 2005 in RAW 264.7 
murine cell line, mouse peritoneal splenocytes and in the mouse spleen following LPS 
stimulation and injection (57). Its importance in the host response to bacterial pathogens 
and its dependency on TLR4 was characterized by Peyssonnaux et al. one year later 
(61) by exposing macrophages and neutrophils to either Gram-positive bacteria or 
Gram-negative bacteria. In vivo data also demonstrated that systemic infection with the 
Gram-negative bacterium P. aeruginosa or the Gram-positive bacterium GAS activated 
hepcidin expression in the liver and in the spleen of mice, ultimately causing serum iron 
level decrease. Mutations in the lipopolysaccharide response locus of TLR4 prevented 
hypoferremic response, iron retention in the spleen and splenic hepcidin induction, but it 
did not affect the hepatic production of hepcidin, suggesting that, at least in this infection 
model, the autocrine production of hepcidin played an important role to reduce FPN 
levels in the spleen and this was required to reduce serum iron levels. On the contrary, 
my data indicated that the lack of hepcidin induction either in the spleen (Figure 3.27B) 
or in the liver (Figure 3.26B) did not affect the hypoferremic response (Figure 3.25) and 
did not prevent splenic iron retention (Figure 3.27F) suggesting that other hepcidin-
independent mechanisms were crucial to mediate these effects during the acute phase 
of inflammation. In BMDMs increased hepcidin mRNA levels were observed only after 
LPS treatment, while incubation of cells with FSL1 did not induce such response. 
Similar results were also obtained with other bacterial lipopeptides that activate TLR2-
dependent signaling (PAM3CSK4 and PamOct2C-(VPG)4VPGKG) suggesting a 
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negligible contribution of TLR2 signaling to hepcidin production in macrophages (Figure 
3.24). Further investigations would be required to clarify the importance of hepcidin 
release from macrophages which may assist the systemic immune response in 
localized infection microenvironments where immune cells are recruited and prompt to 
restrict iron to invading pathogens. However my results suggest that hepcidin 
production is not the only critical line of defense and that, at least in certain 
inflammatory conditions, the hepcidin-independent FPN down regulation represents a 
more relevant and conserved response to restrain iron access. 
 
4.7 Cytokine contribution to the inflammation-mediated regulation of ferroportin and 
hepcidin 
 
4.7.1 The controversial role of TNFα in ferroportin down regulation 
 
The role of cytokines, and in particular, of TNFα in controlling FPN regulation is 
controversial. In support of TNFα-independent FPN down regulation Yang et al. in 2002 
demonstrated that TNFα injection of mice and TNFα treatment of mouse splenocytes 
did not lead to mRNA reduction of FPN. In addition, mice lacking TNFα receptor 
developed hypoferremia following LPS injection and down regulated FPN in the spleen 
to a similar extent as wild type mice (90). Similar results were also obtained in IL6, IL1 
and NFkB1 KO mice indicating that FPN regulation did not require these mediators (57). 
Conversely, two papers in the late eighties reported hypoferremic response in mice in 
consequence of recombinant TNFα injection (180) (181), already suggesting that 
alterations in the ability of macrophages to handle iron was responsible for reduced 
serum iron as recently demonstrated by Schubert et al. in a model of acute inflammation 
(91). My results showed that FSL1 and LPS stimulation while reducing FPN mRNA 
levels, induced TNFα (and other cytokine) mRNA expression in BMDMs (Figure 3.23 C) 
and in the spleens of injected mice (Figure 3.28 A). On the other hand BMDM treatment 
with murine recombinant TNFα induced FPN down regulation throughout a time course 
even with a low dose of the cytokine (Figure 3.33 A). The same was not observed after 
IL6 and IL1β addition (Figure 3.33 B, C) suggesting that TNFα may play a role in the 
FPN transcriptional regulation under inflammatory conditions. Some lines of evidence 
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were also indirectly provided by the TLR6-deficient BMDM response to FSL1, as at 6h 
time point the lack of FPN down regulation was accompanied by the lack of TNFα (and 
not IL6 or IL1β) up regulation (Figure 3.33 D, E). Although promising, these results did 
not address the contribution of TNFα for the systemic FPN regulation which remains to 
be ascertained. 
 
4.7.2 The importance of IL6 and other cytokines for hepcidin induction and hypoferremia 
 
It seems well established that hepatic hepcidin induction during inflammation is 
mediated by IL6 as described in 1.5.4. However the importance of this cytokine for the 
hepcidin regulation in macrophages and for the inflammation-mediated hypoferremic 
response remains controversial.  
In macrophages hepcidin regulation appears to be different between human and mouse 
cells. In particular it was shown that IL6-deficient splenocytes retained the ability to 
increase hepcidin mRNA levels following LPS stimulation (57) while treatment with IL6, 
IL1β and TNFα did not induce hepcidin expression (57, 151). By using different TLR 
ligands, Koening at al. also proved that hepcidin induction in BMDMs occurred either in 
presence or in absence of the translation inhibitor cyclohexemide, further suggesting 
that the new synthesis of cytokines was not required to mediate hepcidin response. 
Significant differences were found in studies of human monocytes which were reported 
to increase hepcidin mRNA levels upon LPS, IL6 or IFNα treatment (182, 183). 
Likewise, in human peripheral blood mononuclear cells (PBMC) IL6 and TGFβ1 were 
shown to induce hepcidin up regulation as well as flagellin (TLR5 agonist) and FSL1 
(66). Consistent with data reported in mice I showed that FSL1 and LPS both activated 
IL1β, IL6 and TNFα mRNA expression throughout a time course, albeit quantitatively 
less in FSL1 treated BMDMs (Figure 3.23). However hepcidin expression was 
upregulated only upon LPS stimulation (Figure 3.22B), indicating that increased 
expression of these cytokines was not sufficient for hepcidin activation in these cells.  
In hepatocytes the importance of IL6 for hepcidin induction was mainly supported by the 
observation that hepcidin response, triggered by FSL1, LPS and other bacterial 
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lipopeptides, was strongly reduced in the absence of this cytokine. (58). Additional 
studies in mice also indicated that IL6 was necessary and sufficient to set hypoferremia 
in a model of acute inflammation using turpentine (55). 
On the contrary, Liu at al. showed that in IL6 knockout mice, serum iron level decreased 
after LPS injection following normal down regulation of splenic and hepatic FPN protein 
(57) suggesting that hepcidin production and hypoferremia were independent of IL6. 
Furthermore IL6-independent hepcidin induction was reported in primary hepatocytes 
as result of IL1α/β treatment (65). Indirect lines of evidence also derived from LPS 
injection in HFE knockout mice which were demonstrated to develop an impaired 
hepcidin response despite a preserved IL6 expression induction (70). My in vivo data 
did not directly address the role of IL6 for hepcidin induction. However I observed that 
FSL1 injection in mice triggered a mild, but significant IL6 mRNA up regulation only in 
the spleen (Figure 3.28 B) while, in the liver, the absence of hepcidin induction 
associated with the lack of IL6 mRNA increase (Figure 3.26 B, D). This may suggest 
either that the levels of circulating IL6, produced by the spleen, were not sufficient to 
induce hepatic hepcidin induction or that the autocrine liver production of IL6 actually 
accounts for hepatic hepcidin stimulation (as the cytokine production observed in the 
spleen appeared not to be sufficient to determine such response). Both these 
hypotheses would require additional investigations. 
 
4.8 The “critical” role of hepcidin in inducing hypoferremia during acute inflammation 
It is widely thought that the hypoferremia associated with acute and chronic 
inflammatory conditions is determined by the induction of hepcidin expression which 
reduces FPN protein amount, diminishing cellular iron export and serum iron levels. 
Injection of a wide range of LPS doses has been reported to induce hepatic hepcidin 
expression and hypoferremia in mice (70, 90) and humans (56) corroborating the link 
between them. However two recent publications have added new insights into the 
inflammation-mediated hypoferremia challenging the belief that hepcidin plays a crucial 
role.  
___________________________________________________________Discussion 
 
115 
By injecting LPS in hepcidin knock-out mice Deschemin and Vaulont (152) showed that 
plasma iron levels significantly decreased irrespective of hepcidin absence. Gene and 
protein expression analyses in the duodenum and in the spleen revealed that FPN 
mRNA levels were strongly reduced in both tissues, while protein levels only decreased 
in the duodenum. In addition, the membrane iron transporter DMT1 and the 
oxidoreductase Dcytb expression were down regulated in the duodenum following LPS 
treatment in hepcidin KO mice as well as in wild type mice leading the authors to the 
conclusion that the observed hypoferremia was the result of compromised iron 
absorption.  
Other lines of evidence questioning the crucial role of hepcidin in the hypoferremic 
response were presented by Layoun et al. (153) who showed that TLR3 activation 
induced acute hypoferremia in absence of hepcidin induction. Interestingly, in the same 
work the analysis of serum iron levels and hepcidin induction after LPS injection 
throughout a time course, indicated that hypoferremia already occurred after 1.5h 
injection, a time point in which hepcidin levels were not yet significantly increased. 
Despite a rapidly LPS-induced hypoferremia, splenic FPN protein appeared to be 
significantly reduced only after 12h from LPS injection, while HFE protein levels showed 
a faster reduction in the spleen. Given the competition between HFE protein and 
transferrin for the same binding site on TfR1, the authors speculated that the 
suppression of HFE may enhance the transferrin-mediated iron uptake in macrophages 
thus contributing to lower circulating iron amount. Through this conclusion they 
assigned a prominent and novel role to HFE in mediating the hypoferremic response 
independent of hepcidin. 
Challenging the prevailing notions and the latest findings, my data showed that 
hypoferremia can be effected in a hepcidin-independent way and that it is mainly 
caused by rapid FPN down regulation. In particular, mice injected with FSL1 and LPS 
both reduced FPN mRNA and protein levels in the liver (Figure 3.26 F) and in the 
spleen (Figure 3.27 C, D) although only LPS-treated mice induced hepcidin mRNA 
expression (Figure 3.26 B). Hypoferremia appeared to be a rapid response triggered by 
both stimuli, as plasma iron and transferrin saturation decreased already after 3h 
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injection (Figure 3.25) and hepatic (Figure 3.26 E) and splenic (Figure 3.27 F) iron 
content increased, indicating iron retention in both tissues. The FPN protein reduction 
observed in the spleen was even more pronounced in magnitude in isolated splenic 
macrophages (Figure 3.27 E), explaining perhaps the difficulty of other authors to 
observe such response. On the other hand, inconsistently with the data presented in 
hepcidin knockout mice, the duodenal analysis I applied did not reveal alterations in the 
iron absorption routes, as, especially in FSL1 injected mice, neither FPN nor DMT1a 
mRNA levels were decreased (Figure 3.29). Following the finding reported about the 
role of HFE in inflammatory hypoferremia, I also analyzed HFE expression after FSL1 
and LPS injection. Reduction in HFE mRNA levels was observed in the spleen of FSL1 
and LPS injected mice, while the liver of LPS injected mice displayed an opposite trend 
(Figure 3.30). However the antibody anti-HFE used in the work of Layoun et al. did not 
meet necessary specificity criteria in my hands, thus preventing additional HFE protein 
analysis in the spleen. 
The direct proof that FSL1-induced hypoferremia and FPN regulation are independent 
of the hepcidin-FPN interaction in vivo was demonstrated in the C326S knock-in mouse 
strain in which the hepcidin/FPN regulatory circuitry was disrupted (190). As anticipated 
in paragraph 1.8.1 this model of non classical ferroportin disease is characterized by 
progressive iron accumulation in many organs and high circulating iron levels due to the 
resistance of FPN to hepcidin binding. The control mediated by hepcidin on FPN is 
completely lost, making these mice a good system to verify the inflammation-mediated 
FPN response irrespective of hepcidin contribution. BMDMs derived from these mice 
treated with FSL1 or LPS induced cytokine expression and regulated FPN expression 
similarly to BMDMs derived from wild type mice (Figure 3.31), already suggesting that 
inflammatory stimuli rather than hepcidin activity were mainly responsible for the strong 
FPN down regulation at mRNA and protein levels. Importantly I demonstrated that 
despite the systemic iron overload developed by these mice, FSL1 significantly reduced 
plasma iron levels within 3 hours and that FPN mRNA and protein levels were 
decreased in the liver as well as in the spleen (Figure 3.32).  
These results demonstrate that hypoferremia can be effected in a hepcidin-independent 
way and assign a crucial role to the hepcidin-independent FPN down regulation in 
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inducing hypoferremia during infection. Hepcidin induction may complement this 
pathway in the generation of hypoferremia and its major contribution may be expressed 
in chronic inflammatory conditions to assist and prolong the hypoferremic response.  
 
Taken together, beside the well-established hepcidin-dependent hypoferremia (induced 
for example by LPS), a complementary hepcidin-independent route can be derived from 
the present study, as represented in the following working model (Figure 4.2): 
 
 
 
Figure 4.2 Working model. (A) According to the current model, TLR4 ligation by LPS induces hepcidin 
release from macrophages via undefined pathways. Hepcidin in turn reduces FPN protein level in an 
autocrine manner. In addition, the release of the inflammatory cytokine IL6 stimulates the hepatic 
hepcidin production which decreases FPN protein amounts in the liver, in the spleen and in the 
duodenum, therefore inhibiting hepatocyte and macrophage iron release and intestinal iron absorption, 
leading to diminished serum iron levels and transferrin saturation (Tf-Fe). (B) The ligation of TLR2/6 by 
FSL1 can mediate a hepcidin-independent hypoferremia by inducing FPN mRNA and protein down 
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regulation in the liver and in the spleen, while FPN expression in the duodenum is unchanged. The 
expression of TLRs on hepatocytes is unclear, leading to the hypothesis that FPN down regulation in this 
cell type is mediated via cytokines or other factors released from the proximate macrophages present in 
the tissue.  
 
4.9 Dissecting the TLR-mediated ferroportin regulation: an “inhibitor approach” 
Given its importance, understanding the molecular mechanism of the FPN transcription 
regulation during inflammation remains a critical point for the development of therapies 
against anemias caused by infectious and inflammatory diseases. 
One way to identify important players of TLR-mediated FPN regulation was to test 
FSL1-induced FPN response after the inhibition of important components of the TLR 
signaling. In 2001 Re and Strominger demonstrated that TLR2 and TLR4 signaling were 
not equivalent and led to differential cytokine and chemokine expression (156). 
Nevertheless their ligation both induced a comparable activation of NFkB and MAPK 
kinases. By using specific inhibitors (Wortmannin and LY294002) these and other 
authors (157) showed in human macrophage cell lines that phosphatidylinositol 3-
kinase (PI3K) was recruited to TLR2 cytosolic domain and that this was required for 
TLR2-mediated signaling to NFkB. In addition, the activation of the TLR pathways upon 
ligation was also demonstrated to be dependent on tyrosine phosphorylation, as protein 
kinase inhibitors and in particular Src kinase inhibitors suppressed TLR2 and TLR4 
phosphorylation and prevented their signaling (157, 158). In particular, Lyn is a member 
of Src kinase family and its deficiency was proven to up regulate cytokine production by 
BMDMs following FSL1 and LPS treatment. The same effect was also observed with 
PI3K inhibition by Wortmannin, while an opposite effect was mediated by SHIP1, the 
protein which hydrolyzes the phospholipid second messenger produced by PI3K 
catalysis (159). Together these lines of evidence suggested that SHIP1 and Lyn/PI3K 
regulated TLR2 and TLR4-induced cytokine production in a positive and negative 
manner, respectively and assigned a crucial role to Src kinase and PI3K in mediating 
the TLRs signaling pathway. Further studies in human macrophage cell lines also 
indicated that other signaling molecules were involved in cytokine expression in 
response to FSL1. Consistently, several inhibitors targeting protein kinase C, PI3K-AKT 
and mitogen-activated protein kinases resulted in significantly attenuated FSL1-mediate 
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cytokine response, indicating that multiple and different classes of molecule controlled 
this signaling(149). For this reason I analyzed the FSL1-mediated FPN mRNA response 
following the inhibition of several classes of molecules listed in Table 3.1 and mostly 
representing kinases. The pre-incubation with none of these inhibitors totally prevented 
the FPN mRNA down regulation, although an attenuated response could be observed 
with the PI3K inhibitor LY294002 (Figure 3.36 A). Interestingly the same blunted effect 
was not observed with the other PI3K inhibitor Wortmannin (Figure 3.36 B) suggesting 
that LY294002 may have a specific effect independent of PI3K inhibition. This 
hypothesis was also supported by the analysis of these inhibitor effects on FPN 
expression in absence of inflammatory stimuli. Both inhibitors induced an increase in 
FPN mRNA levels (Figure 3.35 A). However despite a very transient inhibition of the 
PI3K pathway (monitored by the phosphorylation status of AKT protein) only the 
prolonged treatment with LY294002 induced a strong up regulation of FPN protein level 
(Figure 3.35 C).  This suggested that FPN expression was altered through PI3K-
independent mechanisms and appeared to be consistent with several publications 
reporting diverse effects mediated by LY294002 independent of the PI3K-AKT pathway 
(184-187). 
FPN mRNA amount was also increased by Src kinase inhibition (Figure 3.35 B). 
Nevertheless FSL1 treatment completely overcame such effect down regulating FPN 
expression at the same extent of untreated cells (Figure 3.36 C, D). The regulation of 
FPN mediated by PI3K and Src inhibitors would require further investigations however 
the inhibitor approach I applied was not successful to identify critical elements required 
for FPN response during inflammation. A different approach, like the study of the FPN 
promoter may represent a potential alternative to determine transcription factors and 
promoter binding sites responsible for the FPN mRNA down regulation which I 
demonstrated to be a crucial component of the immune system response during 
inflammation. 
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4.10 Concluding remarks 
The present study aimed at identifying novel regulators of FPN-mediated iron export, 
and, in particular, new molecular mechanisms that controlled FPN internalization and 
degradation. The results obtained from the kinome RNAi screen that I applied and from 
its validation indicated that phosphorylation is not a key modification required for the 
hepcidin-mediated FPN response as believed few years ago. In particular the role of 
JAK2 kinase was not confirmed by the screening analysis consistent with data reported 
in recent publications. 
Few putative regulators of the hepcidin-dependent FPN degradation process were 
identified by the screen. Interestingly, most validated regulators of FPN expression 
conferred hepcidin-independent FPN protein regulation. Some of the putative FPN 
repressors were related to immune processes further corroborating the relationship 
between iron homeostasis and the immune response. 
Specifically, TLR6 was identified as a novel FPN repressor in an engineered HeLa cell 
line and in bone marrow derived macrophages (BMDMs). Its stimulation by FSL1 in 
BMDMs and in mice revealed a hepcidin-independent FPN down regulation sufficient to 
induce inflammatory hypoferremia. This challenges the prevailing notion of the crucial 
role of hepcidin in setting the hypoferremic response and uncovers a rapid and potent 
inflammatory response pathway. 
This work ultimately highlights the importance of the hepcidin-independent FPN 
transcriptional response during inflammation. The identification of molecular players and 
transcriptional factors responsible for this process would bear direct consequences for 
the development of targeted therapies against anemias caused by infectious and 
inflammatory diseases. 
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